

## **Curriculum vitae**

### **Antonio Macciò**

#### Current Professional Activity:

- Full Professor of Gynecology and Obstetrics, Department of Surgical Sciences, University of Cagliari since 01/09/2021
- Head of the Complex Operational Unit of Gynecology and Oncological Gynecology, A. Businco Hospital, Regional Oncology Reference Center, ARNAS (National Referral and Specialized Hospital) G. Brotzu, Cagliari since 01/06/2013
- Head of the Complex Operational Unit of Obstetrics, ARNAS G. Brotzu, Cagliari
- Director of the Department of Oncological Surgery, ARNAS-Brotzu, Cagliari

#### National Scientific Qualification:

- 13/01/2020: Obtained National Scientific Qualification – First Tier (Full Professor) SSD 06/H1 Gynecology and Obstetrics (valid from 13/01/2020 to 13/01/2029)
- 27/05/2019: Obtained National Scientific Qualification – Second Tier (Associate Professor) SSD 06/D3 Oncology (valid from 27/05/2019 to 27/05/2025)
- 02/01/2014: Obtained National Scientific Qualification – First Tier (Full Professor) SSD 06/H1 Gynecology and Obstetrics (valid from 02/01/2014 to 02/01/2020)
- 02/01/2014: Obtained National Scientific Qualification – Second Tier (Associate Professor) SSD 06/H1 Gynecology and Obstetrics (valid from 02/01/2014 to 02/01/2020)

#### Education and Training:

- 03/10/1989: Specialization in Gynecology and Obstetrics at the School of Specialization of the University of Cagliari: Final score 70/70 with honors, defending the thesis titled: “Effect of estradiol benzoate and oxytocin on the response of peripheral lymphocytes to PHA.”
- 22/11/1999: Specialization in Medical Oncology at the School of Specialization in Medical Oncology of the University of Cagliari: Final score 50/50 with honors, defending the thesis titled: “Neoplastic cachexia: role of inflammatory cytokines and leptin.”
- From 1986 to 1989: Three-year Course in Clinical Sexology “Diagnosis, counseling and therapy in sexual dysfunctions” at the Higher School of Clinical Sexology in Rome.
- 20/12/1984: Degree in Medicine and Surgery from the University of Cagliari: Thesis titled “Knowledge-based approach to the etiopathogenesis of abortion: an immunological study” under the supervision of Prof. Salvatore Mancuso, final score 110/110 with honors.

#### Professional, Managerial and Clinical Activity:

- Since 01/06/2013: Head of the Complex Operational Unit of Oncological Gynecology, A. Businco Hospital, Regional Oncology Reference Center, Azienda Ospedaliera Brotzu (Brotzu General Hospital), Cagliari
- Since 17/01/2019: Deputy Director of the Department “Reproduction, Genitourinary, Kidney Diseases and Transplantation” at the Azienda Ospedaliera Brotzu of Cagliari

- From 02/08/1999 to 31/05/2013: Director of the Complex Operational Unit of Gynecology and Obstetrics at Presidio Ospedaliero Sirai (Sirai General Hospital), Carbonia, AUSL 7
- From 13/07/2001 to 02/12/2003: Head of the Oncology Department at Presidio Ospedaliero Sirai, Carbonia, AUSL 7
- From 16/11/2008 to 31/05/2013: Head of the Maternal–Child Department at Presidio Ospedaliero Sirai, Carbonia, AUSL 7
- From 27/10/2004 to 01/01/2006: Coordinator of the Obstetric-Gynecological Area at Presidio Ospedaliero Sirai, Carbonia, AUSL 7
- From 11/11/2004 to 21/12/2005: Substitute Coordinator of the Surgical Area at Presidio Ospedaliero Sirai, Carbonia, AUSL 7
- From 04/11/2009 to 30/06/2010: Health Director of AUSL n°7, Sardinia Region
- From 13/06/2001 to 09/04/2006: Vice-President of the Ethical Committee of AUSL n°7, Carbonia
- From 24/05/1994 to 01/08/1999: Head of the Oncology Section of the Gynecology Department and the Day Hospital Unit at the University Clinic of Obstetrics and Gynecology, University of Cagliari, San Giovanni di Dio Hospital.
- From 16/07/2009 to 16/07/2013: Member of the Regional Oncology Committee, Sardinia Region
- Since 2022: Member of the Regional Endometriosis Committee, Sardinia Region

**Detailed Description of Professional, Managerial and Clinical Activity as Director of the Complex Operational Unit of Oncological Gynecology at A. Businco Hospital, Azienda Ospedaliera Brotzu, Cagliari (since 01/06/2013):**

*Following participation in a national public competition (based on titles and interview) for a Second Level Medical Managerial position for the Directorate of the Complex Operational Unit of Oncological Gynecology at A. Businco Hospital, and having been declared the winner of the said competition, he assumed office on 01 June 2013. From his appointment as Director of the Complex Operational Unit of Oncological Gynecology, he introduced and developed the most advanced laparoscopic surgical techniques in both benign and malignant neoplastic pathology. In particular, at A. Businco Hospital of Azienda Ospedaliera Brotzu in Cagliari, he performed as first operator, 1953 gynecological surgical procedures, of which over 1100 were for definitively malignant neoplastic pathology. Specifically, he has performed:*

- *Radical and total laparoscopic hysterectomies;*
- *Laparoscopic pelvic and para-aortic lymphadenectomies;*
- *Laparoscopic total abdominal omentectomy and peritonectomy;*
- *Laparoscopic splenectomy;*
- *Laparoscopic excision of the diaphragmatic peritoneum;*
- *Laparoscopic resection of the recto-sigmoid and small intestine with end-to-end anastomosis;*
- *Subtotal and total colectomies;*
- *Pelvic evisceration procedures combined with radical hysterectomy + radical cystectomy + recto-sigmoid resection;*
- *Bilateral laparoscopic adnexectomy for locally advanced ovarian carcinoma.*

*He has also performed, as first operator, laparoscopic surgical interventions for the management of complex non-malignant conditions (as indicated by the competences of the Gynecologic Oncologist according to the “Bulletin for Subspecialty Certification in Gynecologic Oncology of the American Board of Obstetrics and Gynecology – January 2020 version”), such as deep endometriosis with severe adhesive*

*syndromes and laparoscopic hysterectomy for fibromatous uteri weighing between 300 grams and 11000 grams.*

*In the same period, at the U.O.C. (Complex Operative Unit) of Oncological Gynecology of A. Businco Hospital, the medical oncology service for the medical treatment of gynecological neoplasms was activated and the unit was authorized as a Prescribing Center for antineoplastic drugs for gynecological tumors monitored according to the AIFA registry. Of particular importance is also the management of oncological patients in advanced stages of disease suffering from disease symptoms – particularly neoplastic cachexia – thanks to the specific expertise acquired by the candidate, as evidenced by numerous international publications on these topics.*

*Within the activities carried out at Azienda Ospedaliera Brotzu in Cagliari, he was also appointed Deputy Director of the Department “Reproduction, Genitourinary, Kidney Diseases and Transplantation” from 17/01/2019 to the present.*

**Detailed Description of Professional Activity as Director of the Complex Operational Unit of Gynecology and Obstetrics at Presidio Ospedaliero Sirai, Carbonia, AUSL n°7 (from 02 August 1999 to 31 May 2013):**

*In June 1999, he participated in a national public competition (based on titles and interview) for a Second Level Medical Managerial position for the Directorate of the Complex Operational Unit of Gynecology and Obstetrics at Presidio Ospedaliero Sirai, Carbonia, AUSL n°7. Having won the competition, he assumed office on 02 August 1999.*

*Within the activities carried out at AUSL n°7, by assignment of the General Director of the Institution, he was given the following tasks:*

- Head of the Maternal–Child Department from 16/11/2008 to 31/05/2013
- Head of the Oncology Department from 13/07/2001 to 02/12/2003
- Coordinator of the Obstetric-Gynecological Area from 27/10/2004 to 01/01/2006
- Substitute Coordinator of the Surgical Area from 11/11/2004 to 21/12/2005
- Vice-President of the Institutional Ethical Committee from 13/06/2001 to 09/04/2006
- Substitute Health Director from 01/11/2004 to 06/10/2005

*As Head of the U.O.C. of Obstetrics and Gynecology at Presidio Ospedaliero Sirai of ASL (Local Health Authority) 7, Carbonia (from his appointment on 02 August 1999), he activated the following services and activities:*

- *Gynecological oncology, gynecology, obstetrics and high-risk pregnancy;*
- *Obstetric and gynecological ultrasound diagnosis, gynecological endoscopy and the service for the diagnosis and treatment of climacteric disorders.*

*Of particular note was the activation of the Day Hospital (D.H.) for medical gynecological oncology. This D.H., created to satisfy the therapeutic needs of patients with malignant neoplasms of the genital apparatus and the breast, also extended its activity to all other neoplastic pathologies present in the territory of Presidio Ospedaliero Sirai, Carbonia. The D.H. operated with two physicians specialized in Medical Oncology and three nursing teams. Furthermore, a psycho-social support service for oncological patients and their families was active thanks to the support of two specialists in psychology and psychopedagogy.*

*Within the operational unit – where activities were carried out following codified protocols and pathways – there was a Gynecology section with 24 beds, an Obstetrics section, and a Medical Oncology Day Hospital equipped with nine chemotherapy chairs. In addition to the Director, the unit comprised 8 specialist medical managers in Obstetrics and Gynecology, 2 in Medical Oncology; the head of the nursing team (nurses dedicated to ward activities, operating room activities and to the activities of the Medical Oncology D.H.); and the head of the midwives and delivery/surgical room staff.*

*Within the Unit, processes and pathways were developed to implement the application of the guidelines issued by international and national scientific societies regarding diagnosis, therapy, and follow-up. Among other initiatives undertaken during this period were: a project to reduce the risk of hospital-acquired infections; the computerization of the U.O.C. with the implementation and use of IT procedures for managing schedules and appointments through the Centralized Appointment Booking System (CUP); activation of the computerized drug cabinet; distribution of drugs to patients upon discharge; activation of pre-hospitalization pathways; implementation of a personnel evaluation system within the U.O.C.; and a project to extend oncological nursing assistance to the territory.*

*In Obstetrics, active participation of the pregnant woman and her partner during labor and delivery was encouraged, with the possibility – in selected cases – of epidural analgesia; and, when requested, early discharge of the new mother was promoted. Courses on birth preparation and pelvic floor rehabilitation were organized by the midwives and gynecologists.*

*In Gynecology, the most modern diagnostic and therapeutic procedures were applied. All minimally invasive and endoscopic techniques (as well as traditional methods) were proposed in the appropriate cases to always provide the best treatment with the shortest hospitalization and fastest recovery. Great care was devoted to informing patients, also via informative leaflets explaining the ward's environment, the techniques used, the pre- and post-operative phases, and providing suggestions for a more serene hospital stay.*

*The Oncology D.H. managed oncological patients through the administration of antineoplastic medical therapy and outpatient follow-up. The D.H. operated with two medical oncology specialists and three nursing staff. Additionally, a psycho-social support service for oncological patients and their families was active, provided by specialists in psychology and psychopedagogy. The Oncology D.H., established to meet the therapeutic needs of patients affected by malignant neoplasms of the genital apparatus and the breast, also extended its activity to all other neoplastic pathologies in the territory of Presidio Ospedaliero Sirai, Carbonia.*

*Special attention was given to collaboration with the patient's primary care physician and external specialists. Upon completion of diagnostic and/or therapeutic procedures, a detailed discharge letter was issued; in cases of video-endoscopic interventions and selected cases, this was accompanied by photographic documentation or a video of the procedure. Upon request, the data were sent via e-mail following privacy regulations. The Gynecology team maintained links with major reference centers in Gynecological Oncology at the national level.*

*In 2004 and again in 2009, the level of results achieved and the professionalism expressed were evaluated by the technical board appointed by ASL n.7 for the renewal (or not) of the Complex Structure assignments. In both cases, the board expressed a judgment "ABOVE AVERAGE" (ASL n.7 deliberations no. 1784 of 27/07/2004 and no. 994 of 15/09/2009).*

*To confirm the above, according to the National Observatory on Women's Health, Presidio Ospedaliero Sirai obtained one "Bollino Rosa" (Pink Label) in 2011 and two "Bollini Rosa" in 2013 for services dedicated to the*

*prevention, diagnosis, and treatment of the main female pathologies*  
(<http://download.repubblica.it/pdf/2013/salute/bollino-rosa/sardegna.pdf>).

**Detailed Description of Professional Activity at the Gynecology and Obstetrics Clinic of the University of Cagliari, San Giovanni di Dio Hospital:**

- 1990: He participated in the national competition (based on titles and examinations) for the role of Medical Assistant in the specialty of Obstetrics and Gynecology at the Obstetrics and Gynecology Clinic of the University of Cagliari, Presidio Ospedaliero San Giovanni di Dio (formerly USL n°20 of Sardinia). Ranking first, he assumed service at the Clinic on 15/04/1991.
- 1994: He took part in the reserved competition (based on titles and examinations) for the role of Deputy Manager at the Gynecology and Obstetrics Clinic of the University of Cagliari (San Giovanni di Dio Hospital) and, ranking first, assumed that role from 24/05/1994.
- From 1991 to 1999: During his activity at the Obstetrics and Gynecology Clinic of the University of Cagliari (formerly USL n°20 and later A n°8), within the scope of the distribution of assistant tasks, he was entrusted by the Clinic Director with the management of Gynecological Oncology—specifically medical oncological therapy—with the role of Head of Department and thus responsible for the Oncology Section of the Gynecology Department and the Day Hospital.

*During this period, of particular note was the increasingly frequent management of patients affected by gynecological malignant neoplasms undergoing antineoplastic medical therapy. This allowed the Clinic, in those years, to autonomously manage not only sophisticated oncological surgical therapy but also antineoplastic medical therapy and its major associated side effects, using the most recently acquired supportive drugs (growth factors, antiemetics, immunomodulators). In addition to these roles, he continued to perform routine assistant tasks (on-call services, assistance at deliveries, operating room activities, and minor surgical interventions such as post-abortion revision of the uterine cavity, diagnostic and therapeutic endometrial curettage, excision or marsupialization of Bartholin gland cyst, etc.). During this period, he also received teaching assignments at the School of Specialization in Gynecology and Obstetrics of the University of Cagliari, at the School of Obstetrics, and at the School for Professional Nurses associated with the Gynecology and Obstetrics Clinic.*

**Surgical Activity:**

Dr. Antonio Macciò has, to date, performed as first operator over 5000 major gynecological surgical procedures. Of these, over 1500 were performed for definitively malignant neoplastic pathologies, including highly complex oncological surgical procedures such as:

- Total, subtotal, and radical laparoscopic hysterectomies (including the laparoscopic removal of a fibromatous uterus weighing up to 11 kg);
- Total peritonectomies, including abdomino-pelvic and diaphragmatic, performed via laparotomy or laparoscopy;
- Pelvic and para-aortic lymphadenectomies performed via laparotomy or laparoscopy;
- Intestinal resections, subtotal and total colectomies, recto-sigmoid resections and small bowel resections with end-to-end, side-to-end anastomoses and colostomies via laparotomy or laparoscopy;
- Laparoscopic ureteral reimplantation;

- Radical cystectomies performed via laparotomy or laparoscopy;
- Total pelvic eviscerations performed via laparotomy or laparoscopy;
- Laparoscopic removal of voluminous adnexal masses, the largest of which weighed over 40 kg.

The following surgical publications attest to this activity (citations remain as in the original):

- Abis P, Madeddu C, Magro Malosso G, Sole G, Mereu A, Locci A, Macciò A. Complicated enterocele: timely resolution with bowel resection via a vaginal approach. Case report. *Frontiers in Surgery*, accepted for publication 28 June 2023.
- Macciò A, Sanna E, Piras R, Lavra F, Vallerino V, Maricosu G, Giglio E, Mura A, Tidore M, Madeddu C. Survival as a clinical outcome and its spiritual significance in a cohort of patients with advanced central pelvic neoplastic disease undergoing total pelvic evisceration: a poorly debated issue. *Front Med (Lausanne)*. 2023 Jun 9;10:1173687. doi: 10.3389/fmed.2023.1173687.
- Maccio A, Madeddu C. Correspondence on "Quality is more important than quantity: pre-operative sarcopenia is associated with poor survival in advanced ovarian cancer" by Polen-De et al. *Int J Gynecol Cancer*. 2022 Nov 7;32(11):1493. doi: 10.1136/ijgc-2022-003916.
- Madeddu C, Sanna E, Nemolato S, Mulas O, Oppi S, Scartozzi M, La Nasa G, Maccio A. Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report. *Diagnostics (Basel)*. 2022 Aug 7;12(8):1910. doi: 10.3390/diagnostics12081910.
- Sanna E, Madeddu C, Lavra F, Oppi S, Scartozzi M, Giorgio Calò P, Macciò A. Laparoscopic management of isolated nodal recurrence in gynecological malignancies is safe and feasible even for large metastatic nodes up to 8 cm: A prospective case series. *Int J Surg*. 2022 Aug;104:106744. doi: 10.1016/j.ijso.2022.106744.
- Sanna E, Chiappe G, Lavra F, Nemolato S, Oppi S, Macciò A, Madeddu C. Diagnostic Framework of Pelvic Massive Necrosis with Peritonitis following Chemoradiation for Locally Advanced Cervical Cancer: When Is the Surgery Not Demandable? A Case Report and Literature Review. *Diagnostics (Basel)*. 2022 Feb 9;12(2):440. doi: 10.3390/diagnostics12020440.
- Macciò A, Donisi C, Sanna E, Chiappe G, Nemolato S, Melis L, Oppi S, Mola B, Madeddu C. Next-Generation Sequencing Whole-Genome Analysis for Targeted Treatment Approach of Metastatic Bartholin Gland Adenocarcinoma: An Emblematic Case Report and Review of the Literature. *Diagnostics (Basel)*. 2021 Nov 10;11(11):2085. doi: 10.3390/diagnostics11112085.
- Macciò A, Sanna E, Lavra F, Chiappe G, Petrillo M, Madeddu C. Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and technique. *BMC Surg*. 2021 Oct 28;21(1):380. doi: 10.1186/s12893-021-01368-z.
- Macciò A, Sanna E, Lavra F, Calò P, Madeddu C. Novel technique of extracorporeal intrauterine morcellation after total laparoscopic hysterectomy: Three emblematic case reports. *World J Clin Cases*. 2021 Jul 16;9(20):5655-5660. doi: 10.12998/wjcc.v9.i20.5655.
- Macciò A, Chiappe G, Kotsonis P, Lavra F, Sanna E, Collu I, Nemolato S, Madeddu C. Feasibility and safety of total laparoscopic hysterectomy for uteri weighing from 1.5 kilograms to 11.000 kilograms. *Archives of Gynecology and Obstetrics*, 2020 Sep 19. doi: 10.1007/s00404-020-05799-6.
- Sanna E, Madeddu C, Melis L, Nemolato S, Macciò A. Laparoscopic management of a giant mucinous benign ovarian mass weighing 10150 grams: A case report. *World J Clin Cases* 8(16):3527-3533.

- Macciò A, Chiappe G, Kotsonis P, Lavra F, Nieddu R, Onnis P, Sanna E, Mais V, Madeddu C. The utility of fibrinogen level as a predictor of complications after laparoscopic gynecologic surgery: a perspective observational study. *Gynecological Surgery* 2019; 2016, Article number 11.
- Macciò A, Kotsonis P, Aste L, Voicu MA, Madeddu C, Conti C, Camparini S. An interdisciplinary approach for laparoscopic removal of a large retroperitoneal pelvic schwannoma attached to vital vessels: A case report. *Medicine (Baltimore)*. 2019;98(51): e18149
- Macciò A, Chiappe G, Lavra F, Sanna E, Nieddu R, Madeddu C. Laparoscopic hysterectomy as optimal approach for 5400 grams uterus with associated polycythemia: A case report. *World J Clin Cases*. 2019 Oct 6;7(19):3027-3032.
- Macciò A, Kotsonis P, Lavra F, Chiappe G, Mura E, Melis L, Madeddu C. A PET-positive rapidly growing mass of the abdominal wall after cesarean section with an unexpected diagnosis of vernix caseosa granuloma: a case report. *A Case Report. Gynecol Surg* 2018 15:17
- Macciò A, Madeddu C, Kotsonis P, Chiappe G, Lavra F, Collu I, Demontis R. Feasibility and safety of total laparoscopic hysterectomy for huge uteri without the use of uterine manipulator: description of two emblematic cases. *Gynecol Surg*. 2018;15(1):6.
- Macciò A, Chiappe G, Kotsonis P, Lavra F, Serra M, Demontis R, Madeddu C. Abdominal leiomyosarcomatosis after surgery with external morcellation for occult smooth muscle tumors of uncertain malignant potential: A case report. *Int J Surg Case Rep*. 2017; 38: 107-110.
- Macciò A, Kotsonis P, Lavra F, Chiappe G, Sanna D, Zamboni F, Madeddu C. Laparoscopic removal of a very large uterus weighting 5320 g is feasible and safe: a case report. *BMC Surg*. 2017;17(1):50.
- Macciò A, Lavra F, Chiappe G, Kotsonis P, Sollai G, Zamboni F, Madeddu C. Combined laparoscopic excisional surgery for synchronous endometrial and rectal adenocarcinoma in an obese woman. *J Obstet Gynaecol*. 2016;36(8):1012-1015.
- Macciò A, Kotsonis P, Chiappe G, Melis L, Zamboni F, Madeddu C. Long-Term Survival in a Patient With Abdominal Sarcomatosis From Uterine Leiomyosarcoma: Role of Repeated Laparoscopic Surgery in Treatment and Follow-Up. *J Minim Invasive Gynecol*. 2016 Sep;23(6):1003-8.
- Macciò A, Chiappe G, Kotsonis P, Nieddu R, Lavra F, Serra M, Onnis P, Sollai G, Zamboni F, Madeddu C. Surgical outcome and complications of total laparoscopic hysterectomy for very large myomatous uteri in relation to uterine weight: a prospective study in a continuous series of 461 procedures. *Arch Gynecol Obstet*. 2016;294(3):525-31.
- Macciò A, Madeddu C, Kotsonis P, Pietrangeli M, Paoletti AM. Large twisted ovarian fibroma associated with Meigs' syndrome, abdominal pain and severe anemia treated by laparoscopic surgery. *BMC Surg*. 2014;14:38.
- Macciò A, Madeddu C, Kotsonis P, Pietrangeli M, Paoletti AM. Successful laparoscopic management of a giant ovarian cyst. *J Obstet Gynaecol*. 2014;34(7):651-2.
- Macciò A, Madeddu C, Kotsonis P, Caffiero A, Desogus A, Pietrangeli M, Paoletti AM. Three cases of laparoscopic myomectomy performed during pregnancy for pedunculated uterine myomas. *Arch Gynecol Obstet*. 2012 Nov;286(5):1209-14.
- Macciò A, Madeddu C, Caffiero A, Paoletti AM. Successful pregnancy following myomectomy of a giant uterine myoma: role of a combined surgical approach. *Arch Gynecol Obstet*. 2012 Jun;285(6):1577-80.

#### Detailed Operative Caseload:

*At the UOC of Oncological Gynecology of Businco Hospital "Regional Reference Center for Cancer Care", Azienda Ospedaliera Brotzu, since 01/06/2013 he has performed as first operator over 2,000 gynecological*

*surgical procedures, of which 1,500 were laparoscopic. (Additional interventions performed between 07/07/2010 and 11/11/2010 are included.)*

*Out of these procedures:*

- *1,137 were for definitively malignant neoplastic pathology (including over 450 for ovarian malignancies, over 350 for uterine malignancies, over 200 for cervical malignancies, over 70 for vulvar malignancies, and over 40 for peritoneal/retroperitoneal malignancies).*
- *Over 200 procedures were performed for ovarian neoplasms of uncertain malignant potential (including voluminous adnexal masses).*
- *As first operator, he performed laparoscopic surgical interventions for complex non-malignant conditions (as per the competencies of the Gynecologic Oncologist according to the “Bulletin for Subspecialty Certification in Gynecologic Oncology of the American Board of Obstetrics and Gynecology – January 2020 version”), specifically 262 procedures for deep endometriosis and 322 procedures for fibromatous uteri weighing between 300 grams and 11 kg, plus over 40 procedures for GIANT OVARIAN CYSTS weighing between 4 and 21 kg.*

*Among the more than 2,000 gynecological surgical procedures performed, the following operations were carried out (classified according to the “Bulletin for Subspecialty Certification in Gynecologic Oncology of the American Board of Obstetrics and Gynecology – January 2020 version”; the classification of radical hysterectomies and lymphadenectomies follows Querleu and Morrow, Lancet Oncol 2008; 9: 297–303):*

- *Vaginal Hysterectomies: 231 procedures (of which 37 were laparoscopically assisted vaginal hysterectomies)*
- *Radical Hysterectomies +/- Bilateral Adnexectomy: 437 procedures, subdivided into:*
  - o *Type A: 129 procedures (100 laparoscopic; 29 via laparotomy)*
  - o *Type B: 185 procedures (137 laparoscopic; 48 via laparotomy)*
  - o *Type C: 108 procedures (75 laparoscopic; 33 via laparotomy)*
  - o *Type D: 15 procedures (6 laparoscopic; 9 via laparotomy)*
- *Total Hysterectomies +/- Bilateral Adnexectomy: 237 procedures, subdivided into:*
  - o *20 via laparotomy*
  - o *253 laparoscopically*
  - o *62 subtotal laparoscopic hysterectomies*
- *Adnexectomies (mono- or bilateral), also for voluminous or giant ovarian cysts: 1,016 procedures*
- *Lymphadenectomies: 365 procedures, divided as:*
  - o *89 Level 1, 127 Level 2, 117 Level 3, 22 Level 4*
- *Inguinal Lymphadenectomies: 20 procedures*
- *Simple and Radical Vaginectomies: 16 procedures*
- *Vulvectomies: 31 procedures*
- *Pelvic Eviscerations: 26 procedures (2 anterior pelvic eviscerations, 11 posteriors, and 13 total pelvic eviscerations [of which 8 were laparoscopic])*
- *Omentectomies: 400 procedures*
- *Intestinal Resections with Re-anastomoses: 162 procedures (50 small intestine; 112 large intestine)*
- *Ileostomies/Colostomies: 41 procedures*
- *Fistula Repairs: 21 procedures*
- *Splenectomies (of which 11 were laparoscopic): 17 procedures*

- Thermoablations or Hepatic Metastasis Excision: 16 procedures
- Diaphragmatic Peritoneum Resections: 24 procedures
- Partial and Total Cystectomies: 29 procedures
- Ureteroileocutaneous Diversions: 17 procedures
- Ureteral Reimplantations: 50 procedures
- Incisions and Drainages for Abdominal and Perineal Abscesses: 6 procedures
- Diagnostic Laparoscopies, Oncological Follow-ups: 132 procedures
- In addition, 103 hysteroscopies and over 110 conizations were performed.

At the U.O.C. of Gynecology and Obstetrics of Sirai Hospital, Carbonia (from 02/08/1999 to 31/05/2013), he performed as first operator over 2,568 gynecological procedures, of which 1,448 were laparoscopic. Among these, he executed:

- 317 total laparoscopic hysterectomies +/- mono or bilateral adnexectomy
- 43 radical laparoscopic hysterectomies of type Be/C
- 481 vaginal hysterectomies, 289 with vaginal reconstruction +/- IUS correction (maximum uterine volume 2,500 grams)
- 154 vaginal hysterectomies with laparoscopic support +/- mono or bilateral adnexectomy
- 308 total laparoscopic hysterectomies +/- mono or bilateral adnexectomy (26 of which were radical, type B and C)
- 6 subtotal laparoscopic hysterectomies (SLH)
- 40 myomectomies via laparotomy (maximum myoma volume > 12 kg)
- 142 diagnostic laparoscopies, oncological follow-up
- 775 operative laparoscopies (including ectopic pregnancies; 25 myomectomies; excisions of ovarian cysts: 94 endometriotic, 34 dermoid; pelvic lymphadenectomies; adnexectomies; salpingectomies; omentectomies, etc. [maximum ovarian cyst removed 42 kg])
- 10 simple or radical vulvectomy
- 200 other gynecological procedures of various natures (exploratory laparotomies, palliative interventions for advanced neoplasms, excision of pelvic masses, colpocleisis, colposacropexy, adhesiolysis, TVT placement). Of these, 296 procedures were for malignant neoplastic pathologies.

He also performed, via laparoscopy or laparotomy:

- 159 pelvic and para-aortic lymphadenectomies,
- 90 infracolic omentectomies,
- 49 appendectomies, and
- 45 total pelvic peritoneum excisions.

Over 300 of his laparotomic and laparoscopic procedures were complicated by moderate-to-severe adhesive syndromes.

As first operator, he additionally performed:

- 864 diagnostic hysteroscopies
- 739 cesarean section operations

Surgical Procedures Performed by the U.O.C. of Gynecology and Obstetrics of Sirai Hospital (in Inpatient Regime):

- *Laparotomic Procedures:* Simple total hysterectomy, hysterectomy with adnexectomy, myomectomy, colposuspension, tubal reanastomosis, Burch procedure, cesarean section (both typical technique and Stark technique).

- *Vulvovaginal and Pelvic Floor Procedures:* Vaginal hysterectomy, vaginal hysterectomy with adnexectomy, simple vulvectomy, colpocleisis, colposuspension, anterior and posterior colpoplasty, TVT (Tension-free Vaginal Tape), modular rectal resection, excision of vaginal cysts, excision/marsupialization of Bartholin gland cysts, external genital reconstruction, endometrial scraping and revision.
- *Laparoscopic Procedures:* Simple total hysterectomy (TLH), subtotal hysterectomy (SLH), LAVH (laparoscopically assisted vaginal hysterectomy), hysterectomy with adnexectomy, laser surgery for endometriosis, myomectomy, treatment of uterine prolapse (sacrohysteropexy/sacrocolpexy), treatment of the vaginal vault (sacrocolpopexy), Burch procedure, presacral neurectomy, LUNA, adnexal cyst excision, adnexectomy/ovariectomy/salpingectomy, chromolaparoscopy, adhesiolysis, ovarian drilling, salpingoneostomy, salpingoscopy, linear salpingotomy in tubal pregnancy treatment, microlaparoscopy/pain mapping.
- *Hysteroscopic Procedures:* Polypectomy, myomectomy, endometrial ablation, uterine malformation correction, intrauterine adhesiolysis, removal of malpositioned IUDs.
- *Oncological Laparotomic Procedures:* Radical hysterectomy (Wertheim-Meigs), total hysterectomy with adnexectomy, simple and radical vulvectomy, pelvic and para-aortic lymphadenectomies, omentectomy, surgical staging.
- *Oncological Laparoscopic Procedures:* Total laparoscopic hysterectomy with adnexectomy, lymphadenectomy, omentectomy, surgical staging.

#### Outpatient Procedures:

- Gynecological ultrasound (transabdominal and transvaginal technique)
- Gynecological Doppler velocimetry
- Colposcopy
- Vulvoscopy
- Peniscopy
- Laser therapy of the lower genital tract
- Diagnostic and operative hysteroscopy

From 15/04/1991 to 01/08/1999 at the Obstetrics and Gynecology Clinic of San Giovanni di Dio Hospital, ASL 8 of Cagliari, he performed the following surgical activity:

- 200 gynecological surgical procedures as second operator;
- 10 gynecological surgical procedures as first operator;
- 300 cesarean sections as first operator.

In total, he performed over 4,500 gynecological surgical procedures as first operator, of which over 2,800 were laparoscopic, specifically:

- Laparoscopic Hysterectomies: 973 (including 344 radical, 561 total, and 68 subtotal laparoscopic hysterectomies)
- Laparotomic Total Hysterectomies: 456 (of which 162 were radical)
- Laparoscopically Assisted Vaginal Hysterectomies: 191
- Vaginal Hysterectomies with or without adnexectomy, anterior and posterior reconstruction: over 700
- Omentectomies: 550
- Intestinal Resections: over 180

- Pelvic Eviscerations: 30
- Ureteral Reimplantations: over 50
- Pelvic and Para-aortic Lymphadenectomies: over 550

Other procedures (such as excision of pelvic peritoneum, total peritoneum, diaphragmatic peritoneum, splenectomies, etc.) are detailed in the operative caseload descriptions of the individual Hospitals at which he performed his activity.

- Additionally, he performed over 1,100 cesarean sections.

#### Training and Scientific Activity:

Since 1986, he has collaborated with Prof. Giovanni Mantovani (former Full Professor of Medical Oncology at the University of Cagliari) in studying tumor immunology, cancer-related inflammatory symptoms, and innovative medical therapies for solid tumors. From 1991, he was Head of Department and subsequently Head of the Oncology Section of the Gynecology Department at the Clinica Ginecologica ed Ostetrica of the University of Cagliari (ASL 8, Sardinia Region). In 1999, he specialized in Medical Oncology as Director of the U.O.C. of Obstetrics and Gynecology at Ospedale Sirai, Carbonia (ASL 7, Sardinia Region). He activated the Gynecological Oncology Unit with an associated Day Hospital for medical therapy of the female genital apparatus and breast. Since 01/06/2013 he has been Director of the U.O.C. of Oncological Gynecology at the Regional Oncology Reference Hospital A. Businco, AO Brotzu, Cagliari.

During his clinical and training activities, Prof. Macciò has developed the key competences defining the Gynecologic Oncologist as reported in the “Bulletin for Subspecialty Certification in Gynecologic Oncology of the American Board of Obstetrics and Gynecology” (January 2020 version), which constitutes the official declaration of the requirements necessary for subspecialization in Gynecological Oncology.

#### Research Activity:

The candidate has continuously carried out both laboratory and clinical research activities in the field of gynecology and obstetrics since the beginning of his career, primarily in the field of gynecological oncology and on the following topics (detailed below):

- Surgery of gynecological neoplasms, particularly with minimally invasive and highly complex surgical techniques;
- The role of the immune system and inflammation in the pathogenesis, prognosis, and symptomatology of malignant gynecological neoplasms;
- Immunology and principles of immunotherapy in solid tumors, especially gynecological and lung cancers;
- Pathophysiology and treatment of cancer-related anemia, particularly in ovarian carcinoma;
- Pathogenesis and prognostic factors in hormone-dependent female tumors, particularly the role of adipose tissue, cytokines, and leptin;
- Pathophysiology and treatment of cancer-related cachexia;
- Therapy for symptoms associated with cancer and its treatments;
- Reproductive immunology.

More recently, he has actively participated in the international scientific debate on the COVID-19 pandemic with the following publications regarding the etiopathogenesis of SARS-COV2-induced coagulopathy:

- Macciò A, La Nasa G, Oppi S, Madeddu C. Defibrotide Has a Role in COVID-19 Therapy. *Chest*. 2022 Aug;162(2):271-273. doi: 10.1016/j.chest.2022.04.143. (Impact Factor: 11.393)
- Macciò A, Oppi S, Madeddu C. COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied? *J Ovarian Res*. 2021 Feb 8;14(1):28. doi: 10.1186/s13048-021-00772-6. (Impact Factor: 5.506)
- Macciò A, Madeddu C, Caocci G, Oppi S, La Nasa G. Defibrotide in the COVID-19 coagulopathy: What is the timing? *J Thromb Haemost*. 2020 Nov;18(11):3113-3115. doi: 10.1111/jth.15100. (Impact Factor: 4.157)
- Macciò A, Madeddu C, Caocci G, La Nasa G. Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders? *J Thromb Haemost*. 2020 Nov;18(11):3106-3108. doi: 10.1111/jth.15021. (Impact Factor: 4.157)
- Maccio A, Madeddu C. Potential role of macrophage activation in mediating thrombotic complications associated with the different vaccines against COVID-19. *Eur Rev Med Pharmacol Sci*. 2021 Oct;25 (20):6176-6178. doi: 10.26355/eurrev\_202110\_26987. (Impact Factor: 3.477)

These research activities have resulted in scientific publications in international peer-reviewed journals, including original articles, reviews, case reports, book chapters, oral presentations, and posters at international and national conferences.

#### Impact of the Overall Scientific Production:

He is the author of:

- 205 international scientific publications as per the ISIWEB database with a total of 4,996 citations, h-index 39 ([http://apps.webofknowledge.com/CitationReport.do?product=UA&search\\_mode=CitationReport&SID=C2GC8AKSKJkUeHz7DIF&page=1&cr\\_pqid=6&viewType=summary](http://apps.webofknowledge.com/CitationReport.do?product=UA&search_mode=CitationReport&SID=C2GC8AKSKJkUeHz7DIF&page=1&cr_pqid=6&viewType=summary))
- 165 articles as per the Scopus database with a total of 5,316 citations, h-index 39 (<https://www.scopus.com/authid/detail.uri?authorId=7004652474>)
- 216 publications according to ResearchGate with a total of 6,474 citations ([https://www.researchgate.net/profile/Antonio\\_Maccio](https://www.researchgate.net/profile/Antonio_Maccio)), h-index 43
- 255 publications according to Google Scholar with a total of 7,826 citations, h-index 47 (<https://scholar.google.it/citations?user=0hBJWksAAAAJ&hl=it>); on this basis, he has been included in the 'Top Italian Scientists (TIS)' classification by VIA-Academy ([http://www.topitalianscientists.org/top\\_italian\\_scientists\\_VIA-Academy.aspx?](http://www.topitalianscientists.org/top_italian_scientists_VIA-Academy.aspx?))
- 161 articles in full text on international journals indexed on PubMed

#### Main Research Areas and Scientific Activity:

Pathogenesis and Prognosis of Malignant Gynecological Neoplasms, in particular the role of the immune system, the tumor microenvironment, and inflammation:

Reference Publications:

Macciò A, Madeddu C. Inflammation and ovarian cancer. *Cytokine*. 2012 May;58(2):133-47 (Impact Factor 3.488), number of citations 245 (notably cited by *Lancet Oncology* 2018; 19 (8):1107-1116);

Macciò A, Madeddu C, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. *Blood*. 2005 Jul 1;106(1):362-7 (Impact Factor 17.543), number of citations 80 (notably cited by *J Clin Oncol* 2010;28:2538-2543);

Macciò A, Lai P, et al. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. *Gynecol Oncol*. 1998 Jun;69(3):248-52 (Impact Factor 4.623), number of citations 70 (notably cited by *JOURNAL OF CLINICAL ONCOLOGY* 2010;28(13):2159-2166):

Macciò A, Madeddu C. The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications – a review. *J Mol Med (Berl)*. 2013;91(12):1355-68 (Impact Factor 4.427), number of citations 33 (notably cited by *NATURE REVIEWS CLINICAL ONCOLOGY* 2018;15(4):234-248);

Macciò A, Madeddu C, et al. Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients. *J Cell Mol Med*. 2009 Sep;13(9B):3951-9 (Impact Factor 4.486), number of citations 21;

Madeddu C, ..., Maccio A. Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of Interleukin-6. *Haematologica* 2018;103(9):e388-e391 (Impact Factor 7.116), number of citations 17;

Macciò A, Gramignano G, Cherchi MC, Tanca L, Melis L, Madeddu C. Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients. *Sci Rep*. 2020;10(1):6096 (Impact Factor 3.998), number of citations 1.

Medical Therapy of Gynecological Neoplasms and Related Symptoms, particularly in advanced stages of disease:

Reference Publications:

Macciò A, Madeddu C, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. *Gynecol Oncol*. 2012 Mar;124(3):417-25 (Impact Factor 4.623), number of citations 71 (notably cited by: *J Clin Oncol* 2020;38:2438. Management of Cancer Cachexia: ASCO Guideline; *CA-A CANCER JOURNAL FOR CLINICIANS* 2015;65(3):190-211; *NATURE REVIEWS DISEASE PRIMERS* 2018;4; *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK* 2016;14(1):82-113. Palliative care version 1.2016);

Macciò A, Madeddu C. Cisplatin: an old drug with a newfound efficacy – from mechanisms of action to cytotoxicity. *Expert Opin Pharmacother*. 2013 Sep;14(13):1839-57 (Impact Factor 3.894), number of citations 36;

Macciò A, Madeddu C, et al. Efficacy and Safety of Oral Lactoferrin Supplementation in Combination with rHuEPO-beta for the Treatment of Anemia in Advanced Cancer Patients Undergoing Chemotherapy: Open-Label, Randomized Controlled Study. *Oncologist*. 2010;15(8):894-902 (Impact Factor 5.025), number of citations 35 (notably cited by *COCHRANE DATABASE OF SYSTEMATIC REVIEWS* 2016;2:CD009624 and by *COCHRANE DATABASE OF SYSTEMATIC REVIEWS* 2014;12:CD010640; *BMJ-BRITISH MEDICAL JOURNAL* 2013;347: f4822. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomized clinical trials);

Madeddu C, Kotsonis P, Lavra F, Chiappe G, Melis L, Mura E, Scartozzi M, Macciò A. Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer. *Oncotarget*. 2019 Mar 12;10(21):2012-2021 (Impact Factor 5.168), number of citations 2;

Macciò A, Madeddu C. The mechanism of cancer cell death by PARP inhibitors goes beyond DNA damage alone. *Int J Cancer*. 2019;145:2594-2596 (Impact Factor 5.145), number of citations 1;  
Macciò A, Madeddu C. Future Prospects for PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Patients With Sarcomas. *JAMA Oncol*. 2018;4(8):1134 (Impact Factor 24.779).

#### Pathophysiology and Treatment of Cancer-Related Anemia:

##### Reference Publications:

Macciò A, Madeddu C, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. *Blood*. 2005 Jul 1;106(1):362-7 (Impact Factor 17.543), number of citations 80 (notably cited by *J Clin Oncol* 2010;28:2538-2543);  
Madeddu C, ..., Maccio A. Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of Interleukin-6. *Haematologica* 2018;103(9):e388-e391 (Impact Factor 7.116), number of citations 17;  
Macciò A, Madeddu C, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. *Haematologica*. 2015 Jan;100(1):124-32 (Impact Factor 7.116), number of citations 77 (notably cited by *Blood* 2019;133:40-50. Anemia of inflammation);  
Macciò A, Madeddu C, et al. Efficacy and Safety of Oral Lactoferrin Supplementation in Combination with rHuEPO-beta for the Treatment of Anemia in Advanced Cancer Patients Undergoing Chemotherapy: Open-Label, Randomized Controlled Study. *Oncologist*. 2010;15(8):894-902 (Impact Factor 5.025), number of citations 35 (notably cited by COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2016;2:CD009624 and by COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2014;12:CD010640; *BMJ-BRITISH MEDICAL JOURNAL* 2013;347: f4822);  
Madeddu C, Gramignano G, Astara G, Demontis R, Sanna E, Atzeni V, Macciò A. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. *Front Physiol*. 2018 Sep 20;9:1294 (Impact Factor 3.367), number of citations 108 (notably cited by *Seminars in Cancer Biology* 2020;65:197-206. The tumor organismal environment: Role in tumor development and cancer immunotherapy).

#### Pathophysiology and Treatment of Neoplastic Cachexia:

##### Reference Publications:

Macciò A, Madeddu C, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. *Gynecol Oncol*. 2012 Mar;124(3):417-25 (Impact Factor 4.623), number of citations 71 (notably cited by: *J Clin Oncol* 2020;38:2438. Management of Cancer Cachexia: ASCO Guideline; *CA-A CANCER JOURNAL FOR CLINICIANS* 2015;65(3):190-211; *NATURE REVIEWS DISEASE PRIMERS* 2018;4; *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK* 2016;14(1):82-113. Palliative care version 1.2016);  
Maccio A, Sanna E, Neri M, Oppi S, Madeddu C. Cachexia as Evidence of the Mechanisms of Resistance and Tolerance during the Evolution of Cancer Disease. *Int J Mol Sci*. 2021;22(6):2890 (Impact Factor 5.923), number of citations 25;  
Macciò A, Madeddu C, Lai E, Scartozzi M. Cancer cachexia and chronic inflammation: an unbreakable bond. *Br J Cancer*. 2023;17:1-2;  
Madeddu C, Busquets S, Donisi C, Lai E, Pretta A, López-Soriano FJ, Argilés JM, Scartozzi M, Macciò A. Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle

Masson M, et al. Impact of Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer. *Cancers*. 2023;15(4):1076;

Macciò A, Madeddu C, Mantovani G. Current pharmacotherapy options for cancer anorexia and cachexia. *Expert Opin Pharmacother*. 2012 Dec;13(17):2453-72 (Impact Factor 3.475), number of citations 27 (notably cited by *CELL* 2015;162(6):1365-1378; *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE* 2015;107: Article Number: djv274);

Madeddu C, Mantovani G, Gramignano G, Macciò A. Advances in pharmacologic strategies for cancer cachexia. *Expert Opin Pharmacother*. 2015;16(14):2163-77 (Impact Factor 2.878), number of citations 19 (notably cited by *COCHRANE DATABASE OF SYSTEMATIC REVIEWS* 2018;2:CD012229. Ghrelin for the management of cachexia associated with cancer);

Madeddu C, Mantovani G, Gramignano G, Astara G, Macciò A. Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches. *Future Oncol*. 2015; 11:2697-2710 (Impact Factor 2.660), number of citations 10;

Mantovani G, Macciò A, et al. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. *Semin Oncol*. 1998;25(2 Suppl 6):45-52, number of citations 135;

Mantovani G, Macciò A, Massa E, Madeddu C. Managing cancer-related anorexia/cachexia. *Drugs*. 2001;61(4):499-514 (Impact Factor 6.189), number of citations 120 (notably cited by *COCHRANE DATABASE OF SYSTEMATIC REVIEWS* 2013;3:CD004310);

Mantovani G, Macciò A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. *Oncologist*. 2010;15(2):200-11 (Impact Factor 5.306), number of citations 119 (notably cited by "Understanding, recognizing, and managing toxicities of targeted anticancer therapies. *CA-A CANCER JOURNAL FOR CLINICIANS* 2013;63:249-279; *ESPEN guidelines on nutrition in cancer patients*. *CLINICAL NUTRITION* 2017;36:11-48);

Mantovani G, Macciò A, Madeddu C, et al. A phase II study with antioxidants, both in the diet and supplemented, pharmacological support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. *Cancer Epidemiol Biomarkers Prev*. 2006 May;15(5):1030-4 (Impact Factor 4.344), number of citations 113 (notably cited by *CA-A CANCER JOURNAL FOR CLINICIANS* 2015;65(3):190-211);

Mantovani G, Macciò A, Esu S, Lai P, Santona MC, Massa E, Dessì D, Melis GB, Del Giacco GS. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. *Eur J Cancer*. 1997 Apr;33(4):602-7 (Impact Factor 7.275), number of citations 81.

#### Supportive Therapy for Cancer-Related Symptoms and Their Treatments:

##### Reference Publications:

Madeddu C, Gramignano G, Astara G, Demontis R, Sanna E, Atzeni V, Macciò A. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. *Front Physiol*. 2018 Sep 20;9:1294 (impact factor 3.367), number of citations 15 (notably cited by *SEMINARS IN CANCER BIOLOGY* 2020; 65:197-206);

Macciò A, Busquets S, Madeddu C, Argilés JM. Editorial: Biological Mechanism-Based and Patient-Centered Management of Cancer-Related Symptoms and Syndromes. *Front Physiol*. 2018;9:1819 (impact factor 3.367), number of citations 1;

Macciò A, Madeddu C, et al.

Efficacy and Safety of Oral Lactoferrin Supplementation in Combination with rHuEPO-beta for the Treatment of Anemia in Advanced Cancer Patients Undergoing Chemotherapy: Open-Label, Randomized Controlled Study.

Oncologist. 2010;15(8):894-902 (Impact Factor 5.025), number of citations 35 (notably cited by COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2016;2:CD009624: The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents; and by COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2014;12:CD010640. Iron therapy in anaemic adults without chronic kidney disease; BMJ-BRITISH MEDICAL JOURNAL 2013;347: f4822. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials);

Macciò A, Madeddu C, Panzone F, Mantovani G.

Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Expert Opin Pharmacother. 2009 Mar;10(4):693-703 (impact factor 2.878), number of citations 19 (notably cited by JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 2015;107:Article Number: djv322; COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2018;2:CD012229);

Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR, Camboni P, Ferreli L, Mocci M, Perboni S, Mura L, Madeddu C, Macciò A.

Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.

Oncol Rep. 2003;10(1):197-206 (impact factor 3.417), number of citations 39.

Immunology and Principles of Immunotherapy in Solid Tumors, in particular in gynecological and lung cancers.

Reference Publications:

Madeddu C, Donisi C, Liscia N, Lai E, Scartozzi M, Macciò A.

EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.

Int J Mol Sci. 2022;23(12):6489; number of citations 24;

Madeddu C, Busquets S, Donisi C, Lai E, Pretta A, López-Soriano FJ, Argilés JM, Scartozzi M, Macciò A.

Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer.

Cancers. 2023;15(4):1076; number of citations 4;

Macciò A, Madeddu C.

Molecular Basis and Advances in Targeted Immunotherapy for Cancer.

International Journal of Molecular Sciences. 2023;24(9):7802;

Macciò A, Madeddu C.

Blocking inflammation to improve immunotherapy of advanced cancer.

Immunology. 2019;159:357-364 (impact factor 5.016), number of citations 29;

Macciò A, Madeddu C.

Future Prospects for PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Patients With Sarcomas.

JAMA Oncol. 2018 Aug 1;4(8):1134 (impact factor 24.779);

Macciò A, Lai P, et al.

High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer.

Gynecol Oncol. 1998 Jun;69(3):248-52 (impact factor 4.623); number of citations 70 (notably cited by JOURNAL OF CLINICAL ONCOLOGY 2010;28(13):2159-2166);

Macciò A, Madeddu C.

Inflammation and ovarian cancer.

Cytokine. 2012 May;58(2):133-47 (Impact Factor 3.488), number of citations 144 (notably cited by Lancet Oncology 2018;19(8):1107-1116);

Macciò A, Madeddu C.

The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review.

J Mol Med (Berl). 2013;91(12):1355-68 (Impact Factor 4.427), number of citations 33 (notably cited by NATURE REVIEWS CLINICAL ONCOLOGY 2018;15(4):234-248);

Macciò A, Madeddu C, et al.

Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients.

J Cell Mol Med. 2009 Sep;13(9B):3951-9 (Impact Factor 4.486), number of citations 21;

Madeddu C, ..., Maccio A.

Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of Interleukin-6.

Haematologica 2018;103(9):e388-e391 (impact factor 7.116), number of citations 17;

Macciò A, Gramignano G, Cherchi MC, Tanca L, Melis L, Madeddu C.

Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients.

Sci Rep. 2020;10(1):6096 (impact factor 3.998), number of citations 1;

Mantovani G, Macciò A, et al.

Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress.

J Mol Med (Berl). 2003;81(10):664-73 (Impact Factor 5.004), number of citations 96;

Mantovani G, Macciò A, et al.

Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status.

Int J Cancer. 2002 Mar 1;98(1):84-91 (Impact Factor 5.145), number of citations 119.

Pathogenesis, Prognostic, and Predictive Factors of Hormone-Dependent Female Tumors.

Reference Publications:

Macciò A, Madeddu C, Gramignano G, Mulas C, Floris C, Massa D, Astara G, Chessa P, Mantovani G.

Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications.

J Mol Med (Berl). 2010;88(7):677-86 (impact factor 5.004), number of citations 73;

Macciò A, Madeddu C, Mantovani G.

Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives.

Obes Rev. 2009;10(6):660-70 (impact factor 7.310), number of citations 50;

Macciò A, Madeddu C.

Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications.

ScientificWorldJournal. 2011;11:2020-36 (impact factor 1.524), number of citations 64 (notably cited by

CANCER RESEARCH 2018;78(7):1713-1725);

Madeddu C, Gramignano G, Floris C, Murenu G, Sollai G, Macciò A.

Role of inflammation and oxidative stress in post-menopausal estrogen-dependent breast cancer.

J Cell Mol Med. 2014 Dec;18(12):2519-29 (impact factor 4.486), number of citations 32 (notably cited by SEMINARS IN CANCER BIOLOGY 2020;60:274-284);

Madeddu C, Sanna E, Gramignano G, Tanca L, Cherchi MC, Mola B, Petrillo M, Macciò A.

Correlation of Leptin, Proinflammatory Cytokines and Oxidative Stress with Tumor Size and Disease Stage of Endometrioid (Type I) Endometrial Cancer and Review of the Underlying Mechanisms.

Cancers. 2022;14(2):268 (Impact Factor 6.639), number of citations 10.

Surgery of Gynecological Neoplasms, in Particular Minimally Invasive and Highly Complex Surgery.

Reference Publications:

Sanna E, Madeddu C, Lavra F, Oppi S, Scartozzi M, Giorgio Calò P, Macciò A.

Laparoscopic management of isolated nodal recurrence in gynecological malignancies is safe and feasible even for large metastatic nodes up to 8 cm: A prospective case series.

Int J Surg. 2022;104:106744 (Impact factor 13.4);

Macciò A, Sanna E, Lavra F, Chiappe G, Petrillo M, Madeddu C.

Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and technique.

BMC Surg. 2021 Oct 28;21(1):380 (Impact factor 2.590);

Macciò A, et al.

Feasibility and safety of total laparoscopic hysterectomy for uteri weighing from 1.5 kilograms to 11.000 kilograms.

Archives of Gynecology and Obstetrics, accepted for publication September 2020. DOI: 10.1007/s00404-020-05799-6 (impact factor 2.283);

Macciò A, et al.

Surgical outcome and complications of total laparoscopic hysterectomy for very large myomatous uteri in relation to uterine weight: a prospective study in a continuous series of 461 procedures.

Arch Gynecol Obstet. 2016 Sep;294(3):525-31 (Impact factor 2.283), number of citations 13;

Macciò A, et al.

Long-Term Survival in a Patient With Abdominal Sarcomatosis From Uterine Leiomyosarcoma: Role of Repeated Laparoscopic Surgery in Treatment and Follow-Up.

J Minim Invasive Gynecol. 2016;23(6):1003-8 (Impact factor 3.107);

Macciò A, et al.

Large twisted ovarian fibroma associated with Meigs' syndrome, abdominal pain and severe anemia treated by laparoscopic surgery.

BMC Surg. 2014 Jun 24;14:38 (Impact factor 1.912), number of citations 13;

Macciò A, et al.

Laparoscopic removal of a very large uterus weighing 5320 g is feasible and safe: a case report.

BMC Surg. 2017;17(1):50 (Impact factor 1.912), number of citations 6;

Macciò A, Madeddu C, Kotsonis P, Caffiero A, Desogus A, Pietrangeli M, Paoletti AM.

Three cases of laparoscopic myomectomy performed during pregnancy for pedunculated uterine myomas.

Arch Gynecol Obstet. 2012 Nov;286(5):1209-14 (Impact factor 2.283), number of citations 7;

Macciò A, Madeddu C, Caffiero A, Paoletti AM.

Successful pregnancy following myomectomy of a giant uterine myoma: role of a combined surgical

approach.

Arch Gynecol Obstet. 2012 Jun;285(6):1577-80 (Impact factor 2.283);

Macciò A, Madeddu C, Kotsonis P, Pietrangeli M, Paoletti AM.

Successful laparoscopic management of a giant ovarian cyst.

J Obstet Gynaecol. 2014;34(7):651-2;

Macciò A, Madeddu C, Kotsonis P, Chiappe G, Lavra F, Collu I, Demontis R.

Feasibility and safety of total laparoscopic hysterectomy for huge uteri without the use of uterine manipulator: description of two emblematic cases.

Gynecol Surg. 2018;15(1):6;

Macciò A, Kotsonis P, Lavra F, Chiappe G, Mura E, Melis L, Madeddu C.

A PET-positive rapidly growing mass of the abdominal wall after cesarean section with an unexpected diagnosis of vernix caseosa granuloma: a case report.

A Case Report. Gynecological Surgery 2018;15:17;

Macciò A, Chiappe G, Kotsonis P, Lavra F, Serra M, Demontis R, Madeddu C.

Abdominal leiomyosarcomatosis after surgery with external morcellation for occult smooth muscle tumors of uncertain malignant potential: A case report.

Int J Surg Case Rep. 2017;38:107-110;

Macciò A, Lavra F, Chiappe G, Kotsonis P, Sollai G, Zamboni F, Madeddu C.

Combined laparoscopic excisional surgery for synchronous endometrial and rectal adenocarcinoma in an obese woman.

J Obstet Gynaecol. 2016 Nov;36(8):1012-1015;

Macciò A, Chiappe G, Lavra F, Sanna E, Nieddu R, Madeddu C.

Laparoscopic hysterectomy as optimal approach for a 5400-gram uterus with associated polycythemia: A case report.

World Journal of Clinical Cases. 2019;7:3027-3032 (impact factor 1.013);

Macciò A, Chiappe G, Kotsonis P, Lavra F, Nieddu R, Onnis P, Sanna E, Mais V, Madeddu C.

The utility of fibrinogen level as a predictor of complications after laparoscopic gynecologic surgery: a perspective observational study.

Gynecological Surgery. 2019;2016, Article number 11;

Sanna E, Madeddu C, Melis L, Nemolato S, Macciò A.

Laparoscopic management of a giant mucinous benign ovarian mass weighing 10150 grams: A case report.

World J Clin Cases. 8(16):3527-3533 (impact factor 1.013).

Immunoendocrinology.

Reference Publications:

Macciò A, Madeddu C, Chessa P, Panzone F, Lissoni P, Mantovani G. Oxytocin both increases the proliferative response of peripheral blood lymphomonocytes to phytohemagglutinin and reverses immunosuppressive estrogen activity. *In Vivo*. 2010;24(2):157-63 (Impact Factor 1.541), number of citations 30;

Macciò A, Madeddu C, Sanna E, Panzone F, Volpe A, Mantovani G. Evidence that human serum with high levels of estrogens interferes with the immune system both by decreasing CD25 expression on T-cells and by increasing interleukin-2 availability. *Reprod Sci*. 2008;15(9):961-9 (Impact Factor 2.616), number of citations 3;

Macciò A, Mantovani G, Turnu E, Artini P, Contu G, Serri FG, Volpe A. Evidence that granulosa cells inhibit interleukin-1 alpha and interleukin-2 production from follicular lymphomonocytes. *J Assist Reprod Genet.* 1993;10(8):517-22 (Impact Factor 2.829), number of citations 12;

Macciò A, Mantovani G, Turnu E, Artini P, Contu G, Volpe A. Preovulatory human follicular fluid in vitro inhibits interleukin-1 alpha, interleukin-2 production and expression of the p55 chain of the IL-2 receptor by lymphomonocytes. *Fertil Steril.* 1994;62(2):327-32 (Impact Factor 6.312), number of citations 9;

#### Organization or Participation as a Speaker at Scientific Conferences in Italy or Abroad

- Scientific Director of the Congress “PARP Inhibitors and Treatment of Patients with Ovarian Carcinoma”, Cagliari, November 25, 2022.
- Scientific Director of the Congress “Ovarian Tumors: New Therapeutic Perspectives and the Role of PARP Inhibitors”, Cagliari, June 11, 2022.
- Scientific Director of the Congress “Next Generation Sequencing in the New Therapeutic Perspectives for BRCA-mutated Ovarian Carcinoma”, Oristano, April 7, 2022.
- Scientific Director of the Congress “Update on New Strategies in Cancer Immunotherapy”, Cagliari, June 26, 2020.
- Scientific Director of the Course for Operating Room Instrument Nurses in Minimally Invasive Surgery, Cagliari, March 22–23; April 12–13; May 10–11; June 7–8, under the patronage of the University of Cagliari (accredited for 50 ECM credits).
- Scientific Director of the Conference “Body, Mind and Cancer” held in Cagliari on December 6–7, 2019.
- Scientific Director of the Congress “FEMALE TUMORS AND SPORTS: A Kick Against Cancer, Information Day”, Cagliari, May 4, 2019.
- Scientific Director and Speaker at the Congress “Interdisciplinary Approach to Ovarian Carcinoma”, Cagliari, December 1, 2018.
- President of the Course “MITO SLIDING DOORS PROJECT. Personalized Therapy in Ovarian Carcinoma”, Cagliari, September 20, 2018.
- Scientific Committee of the National Congress “Taking Care of Women from Conception to Senescence”, Cagliari, July 11–14, 2018.
- Scientific Director and Speaker at the Conference “New Developments in the Therapy of Ovarian and Breast Cancer: A Way Together” held in Cagliari on November 25, 2017.
- Scientific Director of the Scientific Conference “BRCA-mutated Tumors: New Therapeutic Perspectives” held in Cagliari on April 22, 2017.

- Scientific Director of the Scientific Conference “Survival in Oncology: Clinical Outcome and its Spiritual Significance” held in Cagliari on November 12, 2016.
- Member of the Presidium Committee of the Congress “From Caring to Being Able to Care for Women in the Technological Universe of Gynecology and Obstetrics” held in Cagliari on July 13–16, 2016.
- Scientific President and Speaker at the Scientific Conference “Sliding Doors – Personalized Therapy of Ovarian Carcinoma” held in Cagliari on March 2, 2016.
- Scientific President and Speaker at the Conference “Recurrent Ovarian Carcinoma: Diagnostic Framework and Therapeutic Strategies” held in Cagliari on December 18, 2015.
- Scientific Director of the Scientific Conference “The Centrality of Antiangiogenic Therapy in the Treatment of Ovarian Carcinoma” held in Cagliari on November 21, 2015.
- Scientific Coordinator of the Course “1st Day on Ovarian Tumor: Women Listen”, Cagliari, December 13, 2014.
- Scientific Director of the Course “Cancer-Related Symptoms”, Cagliari, November 28, 2014.
- Scientific Director of the Scientific Conference “Role of Biological Drugs in the Therapy of Ovarian Carcinoma: From Etiopathogenesis to Clinical Practice” held in Cagliari on November 22, 2014.
- Scientific Director of the Residential Training Course “Diagnostic and Therapeutic Pathways in Ovarian Carcinoma” held in Sardara on June 26, 2012.
- Director of the 20th National AIUG Congress, Alghero, October 7–9, 2010.
- Scientific Director of the Conference “Therapy of Recurrent Ovarian Carcinoma: Regional Consensus Meeting” held in Oristano on March 19, 2011.
- Scientific Coordinator of the Update Course “Optimizing Antitumor Therapy: Contributions from Research” in Fordongianus (OR), July 3, 2010.
- Director of the Update Course “Global Management of the Neoplastic Patient: The Contribution of Medical Oncology” in Villagrande Strisaili, March 20, 2010.
- Scientific Coordinator and Speaker at the Conference “New Perspectives in the Prevention and Treatment of Hormone-Dependent Breast Carcinoma” held in Guspini on December 4, 2009.
- Director of the Course “Updates in Oncology: Tumors in the Elderly”, Bari Sardo, November 16–17, 2007.

- Director of the Course “Hormone-Dependent Tumors in Women: From Biology to Clinical Practice”, Cagliari, June 30, 2007.
- Director of the Course “Humanizing Cancer Care”, Antiche Terme di Sardara, June 23, 2007.
- Scientific Director of the Scientific Conference “Leptin and Women’s Health” held in Cagliari on September 22–23, 2005.
- Member of the Scientific Board of the IMPRESS Project (Improvement in the Practice of Erythropoiesis), Milan, May 3, 2005.
- Scientific Coordinator of the Congress “Medico-Legal Aspects in Clinical Practice: The Importance of Professional Training and the Use of Therapeutic Practices with Particular Reference to Onco-Hematology”, Cagliari, October 28–29, 2005.
- Scientific Secretariat of the Residential Course “Oxidative Stress and Cancer. Experimental, Clinical Aspects and Therapeutic Perspectives”, Cagliari, June 25–26, 2001, National Academy of Medicine.
- Scientific Secretariat of the Residential Course “Anorexia and Neoplastic Cachexia Syndrome: Etiopathogenesis and Therapy”, Cagliari, June 26–27, 2000, National Academy of Medicine.
- Speaker at the Workshop of the European Society for Gynecologic and Obstetric Investigation: “Growth and Differentiation in Reproductive Organs”, Madonna di Campiglio, Italy, February 6–12, 1994.
- Speaker at the National Congress: “Guidelines in Gynecologic Oncology”, Alghero, October 11–12, 1996.
- Speaker at the Congress of the Italian League Against Tumors: “Interleukin-2 in Oncologic Therapy”, Turin, May 25, 1996.
- Speaker at the Second National Conference of Chief Oncologist Physicians in Hospitals, Milan, March 20–21, 1998.
- Speaker at the Consensus Meeting “Use of Erythropoietin in Gynecologic Tumors”, Rome, March 5, 1999 (National Academy of Medicine).
- Speaker for the Phase III Study Project in Unresectable Non-Microcytic Lung Cancer, Milan, November 12, 1999.
- Speaker at the Congress “New Drugs in the Therapy of Ovarian Carcinoma”, Alghero, May 19, 2001.
- Speaker at the Congress “Eleventh Sardinian Days of Gynecology: New Frontiers in Hormonal Therapies, Assisted Reproduction, and Gynecologic Surgery”, Cagliari, June 20–23, 2001.

- Speaker at the Course “Radio-Chemotherapy-Surgical Integration in Gynecologic Oncology: Update”, Sassari, November 8, 2002.
- Speaker at the Congress “Twelfth Sardinian Days of Gynecology and Obstetrics”, Cagliari, June 27–29, 2002.
- Speaker at the Congress “Cytoprotection: Possibilities in Chemotherapy and Radiotherapy”, Perugia, June 28–29, 2002.
- Discussant at the Consensus Meeting “Management of Anemia in Gynecologic Oncology”, Clusane d’Iseo, July 2, 2003, National Academy of Medicine.
- Speaker at the Course “Current Issues on Menopause”, Olbia, April 11–12, 2003.
- Speaker at the Congress “Algheresi Days of Gynecology and Obstetrics”, Alghero, May 21–24, 2003.
- Speaker at the Congress “Multidisciplinary Teamwork in Oncology”, Carbonia (CA), December 12, 2003 (8 ECM credits).
- Speaker and Tutor at the Stage for Training in Medical Oncology: “Cancer-Related Anorexia/Cachexia. Oxidative Stress and Cancer” held at the University Policlinico of Monserrato – Department of Medical Oncology, Cagliari, April 20–22, 2004 (24 ECM credits).
- Speaker at the “International Workshop on Neonatology: The Surveillance Program for Perinatal Birth and Mortality in the Sardinian Region”, Cagliari, October 28, 2004.
- Speaker at the Congress “Sexuality and Quality of Life in Oncologic Patients”, Cagliari, March 12, 2005.
- Speaker at the International Congress “Courses of Immunotherapy in Cancer”, San Casciano Val di Pesa (FI), June 9–10, 2005.
- Scientific Director and Speaker at the Congress “Medico-Legal Aspects in Clinical Practice: The Importance of Professional Training and the Use of Therapeutic Practices with Particular Reference to Onco-Hematology”, Cagliari, October 28–29, 2005.
- Speaker at the Congress “Live Surgery in Gynecologic Oncology”, Milan, Istituto Europeo di Oncologia, October 25–27, 2005.
- Speaker at the Update Course “Advanced Melanoma: Is There a Role for Interferon?”, Pisa, June 24, 2005.
- Speaker at the Course “Immunoboard Proleukin”, Milan, February 9, 2006.
- Speaker at the Residential Update Course “Clinical Nutrition in Oncology”, University Policlinico of Monserrato, Cagliari, June 23, 2006.

- Speaker at the Training Course “Humanizing Oncology Care: The Patient as Subject of Care”, University Policlinico of Monserrato, Cagliari, May 29, 2006.
- Speaker at the Update Course “Colposcopy and Cervico-Vaginal Pathology”, Cagliari, September 20, 2006.
- Speaker at the Congress “Advances in Gynecological Oncology. 19th National SIOG Congress”, Milan, June 14–16, 2007.
- Speaker at the Extraordinary National AUGUI Congress, Cagliari, June 25–28, 2008.
- Speaker at the Congress “Update in Ovarian Carcinoma”, Sassari, October 18, 2008.
- Speaker at the Congress “Multidisciplinary Diagnosis and Treatment of Lung Tumors”, Cagliari, June 19–20, 2009.
- Speaker at the Symposium of the Italian Society for Menopause: “From Adolescence to Menopause”, Abano Terme (Padua), February 25–26, 2010.
- Speaker at the Scientific Congress “New Developments in the Treatment of Breast Carcinoma” held in Assemini on October 23, 2010.
- Speaker and Tutor at the ESGE-AGUI Course: Theoretical-Practical Workshop on Minimally Invasive Surgery in Gynecology, Cagliari, December 9–11, 2010.
- Speaker at the National Congress “The Twentieth Evolution of Gynecological and Obstetrical Sciences”, Cagliari, June 23–26, 2010.
- Speaker at the Congress “Third Sardinian Days of Obstetric and Gynecological Sciences”, Alghero, May 11–14, 2011.
- Speaker at the Congress “Sexuality Meets Cancer: Opinions, Problems and Solutions in Discussion”, Oliena, May 14, 2011.
- Speaker at the National Congress “Gynecology and Obstetrics of the Third Millennium”, Cagliari, July 9–11, 2012.
- Speaker at the Scientific Congress “Updates in Oncology: Evolution in the Personalization of Oncologic Care: From Targeted Therapy to Supportive Care” held in Sardara on November 17, 2012.
- Speaker at the Scientific Congress “Fourth Sardinian Days of Obstetric and Gynecological Sciences” held in Alghero on May 15–18, 2013.
- Speaker at the 3rd Ravenna Congress “Gender Medicine: The Burden of Being a Woman. From Polycystic Ovary Syndrome to Metabolic Syndrome”, Ravenna, September 21, 2013.

- Speaker at the Scientific Congress “Practical Course in Gynecological and Obstetrical Sciences” held in Cagliari on July 10–12, 2014.
- Speaker at the Congress “Role of Biological Drugs in the Therapy of Ovarian Carcinoma: From Etiopathogenesis to Clinical Practice” held in Cagliari on November 22, 2014.
- Speaker at the Scientific Congress “Fifth Sardinian Days of Obstetric and Gynecological Sciences” held in Alghero on May 21–23, 2015.
- Speaker at the Scientific Congress “1st Sardinian Day of Dermato-Oncology” held in Cagliari on June 13, 2015.
- Speaker at the Congress “Recurrent Ovarian Carcinoma: Diagnostic Framework and Therapeutic Strategies”, Pisa, October 2, 2015.
- Speaker at the Congress “From Caring to Caring for Women in the Technological Universe of Gynecology and Obstetrics” held in Cagliari on July 13–16, 2016.
- Speaker at the Scientific Congress “Metastatic Castration-Resistant Prostate Cancer (mCRPC): Ra223 Dichloride in Clinical Practice” held in Cagliari on November 18, 2016.
- Speaker at the Scientific Congress “Metastatic Castration-Resistant Prostate Cancer (mCRPC): Ra223 Dichloride in Clinical Practice” held in Cagliari on November 18, 2016.
- Speaker at the Scientific Congress “Six Sardinian Days of Obstetric and Gynecological Sciences” held in Alghero on May 18–20, 2017.
- Speaker at the Scientific Congress “Focus on Renal Carcinoma: What’s New?” held in Cagliari on September 27, 2017.
- Scientific Director and Speaker at the Congress “Interdisciplinary Approach to Ovarian Carcinoma”, Cagliari, December 1, 2018.
- Scientific Committee of the National Congress “Taking Care of Women from Conception to Senescence”, Cagliari, July 11–14, 2018.
- President of the Course “MITO SLIDING DOORS PROJECT. Personalized Therapy in Ovarian Carcinoma”, Cagliari, September 20, 2018.
- Speaker at the Congress “BLOG, BRCA in Ovarian Cancer Leading Operational Guidelines”, Cagliari, November 15, 2018.
- Speaker at the Congress “Breast Cancer Update 2018”, Cagliari, November 24, 2018.
- Speaker at the XLII National SICO Congress, Cagliari, September 8–10, 2019.

- Speaker at the National Congress “Seven Sardinian Days of Obstetric and Gynecological Sciences, LOOK BEYOND – THINK DIFFERENT, the New Frontier of Gynecology and Obstetrics”, Alghero, May 15–18, 2018.
- Moderator at the Congress “Focus on PCOS and the Risks of Pathologies in Reproductive Age and in Pregnancy”, Cagliari, June 7, 2019.

Direction or Participation in Editorial Committees of Journals, Editorial Series, Encyclopedias, and Treatises of Recognized Prestige

- Associate Editor at Frontiers in Oncology, Section Breast Cancer (Impact Factor 5.738);
- Guest Associate Editor for Frontiers in Physiology (Impact Factor 4.775), Section Clinical and Translational Physiology;
- Handling Editor for Frontiers in Psycho-oncology (Impact Factor 4.232) and Frontiers in Oncology (Impact Factor 5.738), handling the Breast Cancer, Molecular and Cellular Oncology, Thoracic Oncology, and Cancer Genetics sections;
- Editorial Board Member for the international journal Diagnostics (Impact Factor 3.992);
- Editor for the International Journal of Molecular Sciences, Section “Molecular Oncology” (Impact Factor 6.208, ISSN 1422-0067);
- Editor of the Special Issue entitled “Prognostic Role of White Blood Cells and Platelets Count Changes in Solid Tumors” in Diagnostics (Impact Factor 3.992);
- Editor of the Special Issue entitled “Molecular Basis and Advances of Targeted Immunotherapy for Cancer” in the International Journal of Molecular Sciences (Impact Factor 6.208);
- Editor of the Topical Collection in the International Journal of Molecular Sciences entitled “State-of-the-Art Molecular Immunology in Italy” (Impact Factor 6.208);
- Guest Editor for the International Journal of Molecular Sciences (Impact Factor 6.208, ISSN 1422-0067), Section “Molecular Oncology”, for the Special Issue entitled “Biological and Molecular Mechanisms of Resistance and Tolerance” ([https://www.mdpi.com/journal/ijms/special\\_issues/Neoplastic\\_Disease](https://www.mdpi.com/journal/ijms/special_issues/Neoplastic_Disease));
- Guest Associate Editor for the international, peer-reviewed journal Frontiers in Physiology (Impact Factor 4.775, ISSN 1664-042X), for the Research Topic entitled “Biological Mechanism-Based and Patient-Centered Management of Cancer-Related Symptoms and Syndromes” (<https://www.frontiersin.org/research-topics/4297/biological-mechanism-based-and-patient-centered-management-of-cancer-related-symptoms-and-syndromes>);

- Guest Editor for the journal Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry for the Special Issue “Role of Inflammation in the Evolution of Cancer Disease”; August 2011, 10(4), DOI: 10.2174/187152311797928162;
- Guest Editor of the Special Issue entitled “How Oxidative Stress in Blood Disorders” for the journal Oxidative Medicine and Cellular Longevity (Impact Factor 5.076, ISSN 1942-0900) (<https://www.hindawi.com/journals/omcl/si/952458/>);
- Member of the Editorial Board of:
  - TheScientificWorldJournal, Editorial Board: Obstetrics and Gynecology (<http://www.hindawi.com/journals/tswj/editors/obgyn/>);
  - SM Journal of Gynecology and Obstetrics (<https://smjournals.com/gynecology-obstetrics/editorial-board.php>);
  - SM Journal of Food and Nutritional Disorders (<https://smjournals.com/food-nutritional-disorders/editorial-board.php>);
  - Annals of Nutritional Disorders & Therapy (<https://austinpublishinggroup.com/nutritional-disorders/editorialBoard.php>);
  - Mediators of Inflammation (<http://www.hindawi.com/journals/mi/editors>) from 2011 until August 2017;
  - Participation in the Editorial Committee of the treatise “Cancer-Related Anemia: Clinical Implications, Etiopathogenesis, and Therapeutic Possibilities” by Macciò A, Madeddu C, Mantovani G. Il Pensiero Scientifico Editore. December 2006;
  - Development of Consensus Papers on the Use of Erythropoietin in Gynecological Tumors, participating as speaker and discussant:
    - Consensus Paper: “Use of Erythropoietin in Gynecological Tumors.” Forum, Trends in Experimental and Clinical Medicine, 9.3, Suppl. 4, 1999;
    - “Management of Anemia in Gynecologic Oncology. Consensus Paper.” Edited by Sergio Pecorelli. National Academy of Medicine. Forum Service Editore.

Collaboration as a Reviewer for the following internationally recognized prestigious journals (with the corresponding impact factors):

- New England Journal of Medicine – impact factor 176.079
- Nature Review Cancer – impact factor 69.800
- Nature Reviews Disease Primers – impact factor 65.038
- Cancer Treatment Reviews – impact factor 13.608

- Journal of Cachexia, Sarcopenia and Muscle – impact factor 12.063
- Obesity Review – impact factor 10.867
- Haematologica – impact factor 11.04
- The Lancet Healthy Longevity – impact factor 5.120
- British Journal of Cancer – impact factor 9.075
- Cellular Physiology and Biochemistry – impact factor 5.104
- Journal of Cellular and Molecular Medicine – impact factor 5.295
- Frontiers in Pharmacology – impact factor 5.988
- Frontiers in Oncology – impact factor 5.738
- Frontiers in Nutrition – impact factor 6.590
- Frontiers in Immunology – impact factor 8.786
- Frontiers in Neurology – impact factor 4.086
- Expert Opinion on Investigational Drugs – impact factor 6.498
- Expert Opinion on Investigational Drugs – impact factor 6.498
- Journal of Pain and Symptom Management – impact factor 5.576
- Appetite – impact factor 5.016
- OncoTargets and Therapy – impact factor 4.345
- BMC Cancer – impact factor 4.638
- Mediators of Inflammation – impact factor 4.529
- Cytokine – impact factor 3.926
- Acta Obstetrica et Gynecologica Scandinavica – impact factor 4.544
- Future Oncology – impact factor 3.674
- Cancer Management and Research – impact factor 3.602

- Supportive Care in Cancer – impact factor 3.359
- Biomarkers – impact factor 2.663
- BMC Women’s Health – impact factor 2.742
- Cancer Investigation – impact factor 2.368
- Current Pharmaceutical Biotechnology – impact factor 2.829
- European Journal of Obstetrics & – impact factor 2.831
- Gynecology and Reproductive Biology
- Expert Review of Endocrinology and Metabolism – impact factor 0.430
- BMJ Case Reports – impact factor 0.170
- Journal of Medicine and Medical Sciences – impact factor 0.340
- International Journal of Women's Health
- Biology
- Patient Related Outcome Measures
- Seminars in Arthritis and Rheumatism
- The Research and Biology of Cancer
- Tumor Biology
- Tumori

#### Direction or Participation in Research Groups with National or International Collaborations

- International collaboration with the research group “Biochemistry and Molecular Biology of Cancer Research Group” led by Prof. Josep Argilés of the University of Barcelona since 2011. This collaboration has so far resulted in full publications or conference presentations of several clinical and experimental studies in collaboration (e.g., Busquets S, Serpe R, Toledo M, Betancourt A, Marmonti E, Orpí M, Pin F, Capdevila E, Madeddu C, López-Soriano FJ, Mantovani G, Macciò A, Argilés JM. L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer. Clin Nutr. 2012;31:889-95; The cachexia score (CASCO) as a tool for staging cachectic cancer patients. J Clin Oncol 32, 2014 Suppl; abstract e20700). This collaboration also led in 2016 to the

publication of a Research Topic in *Frontiers in Physiology* (Impact Factor 4.031) entitled “Biological Mechanism-Based and Patient-Centered Management of Cancer-Related Symptoms and Syndromes” – Editors: Silvia Busquets, Antonio Macciò, Josep Argilés and Clelia Madeddu (<http://journal.frontiersin.org/research-topics/4297/biological-mechanism-based-and-patient-centered-management-of-cancer-related-symptoms-and-syndromes>).

- Participation with the research group of Prof. Tomas Ganz, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, which led to the following international publication in a peer-reviewed journal: Macciò A, Madeddu C, Gramignano G, Mulas C, Tanca L, Cherchi MC, Floris C, Farci D, Pretta A, Scartozzi M, Macciò A, Argilés JM, Ganz T. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. *Haematologica*. 2015;100(1):124-32; DOI: 10.3324/haematol.2014.112813
- Collaboration with Dr. Itaru Omoto of Kagoshima University, which resulted in the following international publication in a peer-reviewed journal: Macciò A, Madeddu C, Gramignano G, Mulas C, Tanca L, Cherchi MC, Floris C, Omoto I, Barracca A, Ganz T. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. *Haematologica*. 2015;100(1):124-32; DOI: 10.3324/haematol.2014.112813

Responsibility for studies and research projects commissioned by qualified public or private institutions.

- Participation in the Research Project e.INS - Project PNRR – EI- e.INS Ecosystem of Innovation for Next Generation Sardinia - (CODICE MUR ECS0000038)
- Participation in the Research Project PNRR - PIS:fi – HEAL- ITALIA - Health Extended Alliance for Innovative Therapies, Advanced Lab-research, and Integrated Approaches of Precision Medicine (CODICE MUR PE0000019)
- Participation in Research Project No. 2021.1517 (Prot.U951.2021/AI.931.BE) entitled “Spiritual and Psychosocial Well-being and Prognosis in Patients with Gynecological Neoplasms”, funded by “Fondazione Banco di Sardegna” from 12/02/2021 to 12/02/2022.
- Scientific Director of the Research Project entitled “PROTAM trial: Prognostic and Predictive Role of Macrophage Polarization in the Tumor Microenvironment in Ovarian Carcinoma” funded by Sardegna Ricerche under the “I FAIR - Valorization of Independent and FAIR Clinical Research” call DET DG 1644 PST DEL 16/12/2019 and DET DG 8 of 07/01/2020 ([https://www.sardegna ricerche.it/documenti/13\\_398\\_20200305124012.pdf](https://www.sardegna ricerche.it/documenti/13_398_20200305124012.pdf)).
- Scientific Director of Research Project No. 2014.1883 entitled “Advanced Ovarian Carcinoma as an Immunological, Endocrine, and Metabolic Disorder. A Translational Research Project for the Development of an Integrated Targeted Approach to Tumor-Associated Symptoms”, funded by “Fondazione Banco di Sardegna” for the biennium 2014–2015.
- Participation in the National Research Project funded by MIUR, PRIN 2006–2008 entitled “Phase III Randomized Clinical Trial to Evaluate the Efficacy and Tolerability of an Integrated Treatment (Dietary, Pharmaconutritional, and Pharmacological) in Neoplastic Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress” (Protocol Code 2006067295\_001), Scientific Coordinator Prof. Giovanni Mantovani.

- Participation in the National Research Project funded by MIUR, PRIN 2004–2006 entitled “Cancer-Related Anorexia/Cachexia and Oxidative Stress: An Innovative Dietary, Pharmaconutritional, and Pharmacological Treatment Approach”.
- Participation in the two-year National Research Project entitled “Integrated Hormonal (Progestins), Immunotherapeutic (Interleukin-2), and Chemotherapeutic Treatment in Human Solid Tumors. Preliminary Results in Primary Non-Small Cell Lung Carcinoma”, under the PRIN 1999–2001 funded by MIUR, Scientific Coordinator Prof. Giovanni Mantovani.
- Reviewer of research projects for the following prestigious international entities: Swiss National Foundation, Bern, Switzerland, (year 2016); Barts and London Charity, London, UK, (year 2010).

Scientific responsibility for international and national research projects, funded on the basis of competitive calls with peer review.

- (Repeated) Participation in the Research Project e.INS - Project PNRR – EI- e.INS Ecosystem of Innovation for Next Generation Sardinia - (CODICE MUR ECS00000038)
- Participation in the Research Project PNRR - PIS:fi – HEAL- ITALIA - Health Extended Alliance for Innovative Therapies, Advanced Lab-research, and Integrated Approaches of Precision Medicine (CODICE MUR PE0000019)
- Participation in Research Project No. 2021.1517 (Prot.U951.2021/AI.931.BE) entitled “Spiritual and Psychosocial Well-being and Prognosis in Patients with Gynecological Neoplasms”, funded by “Fondazione Banco di Sardegna” from 12/02/2021 to 12/02/2022.
- Scientific Director of the Research Project entitled “PROTAM trial: Prognostic and Predictive Role of Macrophage Polarization in the Tumor Microenvironment in Ovarian Carcinoma” funded by Sardegna Ricerche under the I FAIR Program.
- Scientific Director of Research Project No. 2014.1883 entitled “Advanced Ovarian Carcinoma as an Immunological, Endocrine, and Metabolic Disorder. A Translational Research Project for the Development of an Integrated Targeted Approach to Tumor-Associated Symptoms”, funded by “Fondazione Banco di Sardegna” for the biennium 2014–2015.
- Participant in the National Research Program funded by MIUR, PRIN 2006–2008 entitled “Phase III Randomized Clinical Trial to Evaluate the Efficacy and Tolerability of an Integrated Treatment (Dietary, Pharmaconutritional, and Pharmacological) in Neoplastic Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress”.
- Participant in the National Research Project funded by MIUR, PRIN 2004–2006 entitled “Cancer-Related Anorexia/Cachexia and Oxidative Stress: An Innovative Dietary, Pharmaconutritional, and Pharmacological Treatment Approach”.
- Participant in the two-year National Research Project (PRIN 1999–2001) funded by MIUR entitled “Integrated Hormonal (Progestins), Immunotherapeutic (Interleukin-2), and Chemotherapeutic Treatment in Human Solid Tumors. Preliminary Results in Primary Lung Carcinoma”, Scientific Coordinator Prof. Giovanni Mantovani.

### Teaching Activity

Formal assignment of teaching or research duties at qualified universities and research institutes, including international or supranational ones:

- Teaching assignment in Gynecology and Obstetrics in the Degree Course in Medicine and Surgery from Academic Year 2021–2022 to present.
- Coordinator and Lecturer of the Integrated Course on Physiology of Human Reproduction, General Hygiene, and Prevention in the Degree Course in Midwifery (required for the midwifery profession).
- Coordinator and Lecturer of the Integrated Course on BENIGN AND MALIGNANT GYNECOLOGICAL PATHOLOGY in the Degree Course in Midwifery.
- Teaching assignment in Gynecologic Oncology in the Medical Oncology Specialization School (3rd year), Faculty of Medicine, University of Cagliari from Academic Year 2018–2019 to present.
- Visiting Professor at the Specialization School in Gynecology and Obstetrics (teaching “CYTOKINES AND CANCER IN GYNECOLOGY” 4th year), Faculty of Medicine, University of Cagliari, Academic Year 2012–2013.
- Visiting Professor at the Specialization School in Gynecology and Obstetrics for the course “Adjuvant Therapy in Gynecological Tumors”, for the fourth year of the said School, 1992–1998.
- Teaching “Principles of Immunology” at the Midwifery School, attached to the Obstetrics and Gynecology Clinic of the University of Cagliari, Academic Years 1991–1998.
- Teaching “Immunohematology” at the School for Professional Nurses, attached to the Obstetrics and Gynecology Clinic of the University of Cagliari, Academic Years 1991–1997.
- Teaching “General Concepts of Immunology” at the School for Professional Nurses, attached to the Obstetrics and Gynecology Clinic of the University of Cagliari, Academic Years 1991–1997.
- Teaching “Psychiatric Rehabilitation Sciences (psychiatry, rehabilitation techniques)” in the 2nd year of the Degree Course in Psychiatric Rehabilitation Techniques, Faculty of Medicine and Surgery, University of Cagliari, Academic Year 2010/2011.
- Teaching “Physiology” in the 1st year of the Degree Course in Psychiatric Rehabilitation Techniques, Faculty of Medicine and Surgery, University of Cagliari, Academic Year 2009–2010.
- Participation in the Faculty Board for the assignment of teaching duties within accredited PhD programs:
- Member of the Faculty Board for the PhD Program entitled “CAPACITIES BUILDING FOR GLOBAL HEALTH”, Academic Year starting 2023/2024, Proposing University: University of Cagliari.

### List of Main Full Scientific Publications in International Peer-Reviewed Journals (according to ISIWEB of Science and SCOPUS):

- Madeddu C, Lai E, Neri M, Sanna E, Gramignano G, Nemolato S, Scartozzi M, Giglio S, Macciò A. Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous

Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics. *Int J Mol Sci.* 2025;26(5):2232. Impact factor 4.9

- Macciò A, Vallerino V, Sole G, Nemolato S, Giglio E, Madeddu C. Successful laparoscopic cytoreductive surgery for multiple (three) advanced recurrences of AGCT in a young woman. A case report. *Int J Surg Case Rep.* 2025 Feb;127:110960. doi: 10.1016/j.ijscr.2025.110960. Epub 2025 Jan 27. PMID: 39874807; PMCID: PMC11808675. Impact factor 0.6
- Macciò A, Madeddu C. Cancer is not a guest. *Transl Oncol.* 2025 Jan;51:102162. doi: 10.1016/j.tranon.2024.102162. Epub 2024 Oct 28. PMID: 39490055; PMCID: PMC11576533. Impact factor 4.5
- Madeddu C, Gramignano G, Lai E, Pinna G, Tanca L, Cherchi MC, Floris C, Farci D, Pretta A, Scartozzi M, Macciò A. Leptin as a surrogate immune-metabolic marker to predict the impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors. *ESMO Open.* 2024 Oct;9(10):103738. doi: 10.1016/j.esmoop.2024.103738. Epub 2024 Oct 10. PMID: 39389003; PMCID: PMC11693429. Impact factor 7.1
- Macciò A, Abis P, Sole G, D'Angelo N, Nemolato S, Madeddu C. A giant pelvic infiltrating schwannoma misdiagnosed as an ovarian neoplasm that was resected using a laparoscopic approach: A case report. *Int J Surg Case Rep.* 2024 Sep;122:110138. doi: 10.1016/j.ijscr.2024.110138. Epub 2024 Aug 10. PMID: 39128216; PMCID: PMC11367093. Impact factor 0.6
- Abis P, Madeddu C, Magro Malosso G, Sole G, Mereu A, Locci A, Macciò A. Complicated enterocele: timely resolution with bowel resection via a vaginal approach. *Case report. Frontiers in Surgery,* accepted for publication 28 June 2023. Impact factor 2.568
- Macciò A, Sanna E, Piras R, Lavra F, Vallerino V, Maricosu G, Giglio E, Mura A, Tidore M, Madeddu C. Survival as a clinical outcome and its spiritual significance in a cohort of patients with advanced central pelvic neoplastic disease undergoing total pelvic evisceration: a poorly debated issue. *Front. Med.* 2023; 10:1173687. Impact factor 5.058
- Macciò A, Madeddu C. Molecular Basis and Advances in Targeted Immunotherapy for Cancer. *International Journal of Molecular Sciences.* 2023; 24(9):7802. Impact factor 6.208
- Macciò A, Madeddu C, Lai E, Scartozzi M. Cancer cachexia and chronic inflammation: an unbreakable bond. *Br J Cancer.* 2023; 17:1–2. Impact factor 9.075
- Madeddu C, Busquets S, Donisi C, Lai E, Pretta A, López-Soriano FJ, Argilés JM, Scartozzi M, Macciò A. Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer. *Cancers.* 2023;15(4):1076 Impact factor 6.575
- Mulas O, Mola B, Madeddu C, Caocci G, Macciò A, Nasa G. Prognostic Role of Cell Blood Count in Chronic Myeloid Neoplasm and Acute Myeloid Leukemia and Its Possible Implications in Hematopoietic Stem Cell Transplantation. *Diagnostics.* 2022;12(10):2493.
- Impact factor 3.992 Macciò A, Madeddu C. Correspondence on "Quality is more important than quantity: pre-operative sarcopenia is associated with poor survival in advanced ovarian cancer" by Polen-De et al. *Int J Gynecol Cancer.* 2022;32(11):1493. Impact factor 4.661

- Madeddu C, Sanna E, Nemolato S, Mulas O, Oppi S, Scartozzi M, La Nasa G, Macciò A. Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report. *Diagnostics (Basel)*. 2022;12(8):1910. Impact factor 3.992
- Macciò A, La Nasa G, Oppi S, Madeddu C. Defibrotide Has a Role in COVID-19 Therapy. *Chest*. 2022;162(2):271-273. Impact factor 11.393
- Sanna E, Madeddu C, Lavra F, Oppi S, Scartozzi M, Giorgio Calò P, Macciò A. Laparoscopic management of isolated nodal recurrence in gynecological malignancies is safe and feasible even for large metastatic nodes up to 8 cm: A prospective case series. *Int J Surg*. 2022;104:106744. Impact factor 13.4
- Madeddu C, Donisi C, Liscia N, Lai E, Scartozzi M, Macciò A. EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment. *Int J Mol Sci*. 2022;23(12):6489. Impact factor 6.208
- Sanna E, Chiappe G, Lavra F, Nemolato S, Oppi S, Macciò A, Madeddu C. Diagnostic Framework of Pelvic Massive Necrosis with Peritonitis following Chemoradiation for Locally Advanced Cervical Cancer: When Is the Surgery Not Demandable? A Case Report and Literature Review. *Diagnostics*. 2022; 12(2):440. Impact factor 3.706
- Madeddu C, Sanna E, Gramignano G, Tanca L, Cherchi MC, Mola B, Petrillo M, Macciò A. Correlation of Leptin, Proinflammatory Cytokines and Oxidative Stress with Tumor Size and Disease Stage of Endometrioid (Type I) Endometrial Cancer and Review of the Underlying Mechanisms. *Cancers*. 2022; 14(2):268. Impact factor 6.639
- Macciò A, Donisi C, Sanna E, Chiappe G, Nemolato S, Melis L, Oppi S, Mola B, Madeddu C. Next-Generation Sequencing Whole-Genome Analysis for Targeted Treatment Approach of Metastatic Bartholin Gland Adenocarcinoma: An Emblematic Case Report and Review of the Literature. *Diagnostics* 2021; 11: 2085. Impact factor 3.706
- Macciò A, Madeddu C. Potential role of macrophage activation in mediating thrombotic complications associated with the different vaccines against COVID-19. *Eur Rev Med Pharmacol Sci*. 2021;25(20):6176-6178. Impact factor 3.507
- Macciò A, Sanna E, Lavra F, Chiappe G, Petrillo M, Madeddu C. Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and technique. *BMC Surg*. 2021 Oct 28;21(1):380. Impact factor 2.590
- Sanna E, Tanca L, Cherchi C, Gramignano G, Oppi S, Chiai MG, Macciò A, Madeddu C. Decrease in Neutrophil-to-Lymphocyte Ratio during Neoadjuvant Chemotherapy as a Predictive and Prognostic Marker in Advanced Ovarian Cancer. *Diagnostics (Basel)*. 2021;11(7):1298. Impact factor 3.706
- Macciò A, Sanna E, Lavra F, Calò PG, Madeddu C. Novel technique of extracorporeal intrauterine morcellation after total laparoscopic hysterectomy: Three emblematic case reports. *World J Clin Cases* 2021; 9(20):5655-5660. Impact factor 1.337
- Madeddu C, Neri M, Sanna E, Oppi S, Macciò A. Experimental Drugs for Chemotherapy- and Cancer-Related Anemia. *J Exp Pharmacol*. 2021;13:593-611. Impact factor 3.5

- Maccio A, Sanna E, Neri M, Oppi S, Madeddu C. Cachexia as Evidence of the Mechanisms of Resistance and Tolerance during the Evolution of Cancer Disease. *Int J Mol Sci.* 2021; 22(6):2890 Impact factor 5.923
- Macciò A, Oppi S, Madeddu C. COVID-19 and cytokine storm syndrome: Can what we know about interleukin-6 in ovarian cancer be applied? *J Ovarian Res.* 2021 ;14(1):28. Impact Factor: 2.999
- Macciò A, Chiappe G, Kotsonis P, Lavra F, Sanna E, Collu I, Nemolato S, Madeddu C. Feasibility and safety of total laparoscopic hysterectomy for uteri weighing from 1.5 kilograms to 11.000 kilograms. *Arch Gynecol Obstet.* 2021;303(1):169-179. Impact Factor 2.283
- Macciò A, Madeddu C, Caocci G, Oppi S, La Nasa G. Defibrotide in the COVID-19 coagulopathy: what is the timing? *J Thromb Haemost.* 2020 Sep 18. doi: 10.1111/jth.15100. Epub ahead of print. PMID: 32945111. Impact factor 4.157
- Sanna E, Madeddu C, Melis L, Nemolato S, Macciò A. Laparoscopic management of a giant mucinous benign ovarian mass weighing 10150 grams: A case report. *World J Clin Cases* 8(16):3527-3533. DOI: 10.12998/wjcc.v8.i16.3527. PMID: 32913859; PMCID: PMC7457110. Impact factor 1.013
- Macciò A, Madeddu C, Caocci G, La Nasa G. Multifactorial pathogenesis of COVID-19-related coagulopathy. Can defibrotide have a role in the early phases of coagulation disorders? [published online ahead of print, 2020 Jul 21]. *J Thromb Haemost.* 2020 Jul 21:10.1111/jth.15021. doi: 10.1111/jth.15021. Epub ahead of print. PMID: 32692894 Impact factor 4.157
- Macciò A, Gramignano G, Cherchi MC, Tanca L, Melis L, Madeddu C. Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients. *Sci Rep.* 2020;10(1):6096. DOI: 10.1038/s41598-020-63276-1. PMID: 32269279; PMCID: PMC7142107. Impact factor 3.998
- Macciò A, Madeddu C. Blocking inflammation to improve immunotherapy of advanced cancer. *Immunology.* 2020;159(4):357-364. DOI: 10.1111/imm.13164. PMID: 31821533; PMCID: PMC7078000 Impact factor 5.016
- Macciò A, Kotsonis P, Aste L, Voicu MA, Madeddu C, Conti C, Camparini S. An interdisciplinary approach for laparoscopic removal of a large retroperitoneal pelvic schwannoma attached to vital vessels: A case report. *Medicine* 2019;98(51): e18149. DOI: 10.1097/MD.00000000000018149. PMID: 31860962; PMCID: PMC6940178. Impact factor 1.552
- Macciò A, Chiappe G, Kotsonis P, Lavra F, Nieddu R, Onnis P, Sanna E, Mais V, Madeddu C. The utility of fibrinogen level as a predictor of complications after laparoscopic gynecologic surgery: a perspective observational study. *Gynecol Surg.* 2019; 2016, Article number 11. DOI: 10.1186/s10397-019-1064-x.
- Macciò A, Chiappe G, Lavra F, Sanna E, Nieddu R, Madeddu C. Laparoscopic hysterectomy as optimal approach for 5400 grams uterus with associated polycythemia: A case report. *World Journal of Clinical Cases* 2019;7: 3027-3032. DOI: 10.12998/wjcc.v7.i19.3027. PMID: 31624750; PMCID: PMC6795742. Impact factor 1.013

- Macciò A, Madeddu C. The mechanism of cancer cell death by PARP inhibitors goes beyond DNA damage alone. *Int J Cancer*. 2019;145(9):2594-2596. DOI: 10.1002/ijc.32392. PMID: 31070782. Impact factor 5.145
- Madeddu C, Kotsonis P, Lavra F, Chiappe G, Melis L, Mura E, Scartozzi M, Macciò A. Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer. *Oncotarget*. 2019;10(21):2012-2021. DOI:10.18632/oncotarget.26769. PMID: 31007844 Impact factor 5.168
- Macciò A, Busquets S, Madeddu C, Argilés JM. Editorial: Biological Mechanism-Based and Patient-Centered Management of Cancer-Related Symptoms and Syndromes. *Front Physiol*. 2018;9:1819. DOI: 10.3389/fphys.2018.01819. PMID: 30618829; PMCID: PMC6305426. Impact factor 3.367
- Madeddu C, Gramignano G, Astara G, Demontis R, Sanna E, Atzeni V, Macciò A. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. *Front Physiol*. 2018 Sep 20;9:1294. DOI: 10.3389/fphys.2018.01294. PMID: 30294279

Impact factor 3.367

- Macciò A, Madeddu C. Future Prospects for PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Patients With Sarcomas. *JAMA Oncol*. 2018;4(8):1134. DOI: 10.1001/jamaoncol.2018.0875. Impact factor 24.799
- Madeddu C, Gramignano G, Kotsonis P, Coghe F, Atzeni V, Scartozzi M, Macciò A. Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of Interleukin-6. *Haematologica*. 2018;103(9):e388-e391. DOI: 10.3324/haematol.2018.191551. Impact factor 7.116
- Maccio A, Kotsonis P, Lavra F et al. A PET-positive rapidly growing mass of the abdominal wall after cesarean section with an unexpected diagnosis of vernix caseosa granuloma: a case report. *Gynecol Surg*. 2018;1 (17). DOI: 10.1186/s10397-018-1050-8.
- Macciò A, Madeddu C, Kotsonis P, Chiappe G, Lavra F, Collu I, Demontis R. Feasibility and safety of total laparoscopic hysterectomy for huge uteri without the use of uterine manipulator: description of two emblematic cases. *Gynecol Surg*. 2018;15(1):6. DOI: 10.1186/s10397-018-1037-5
- Macciò A, Chiappe G, Kotsonis P, Lavra F, Serra M, Demontis R, Madeddu C. Abdominal leiomyosarcomatosis after surgery with external morcellation for occult smooth muscle tumors of uncertain malignant potential: A case report. *Int J Surg Case Rep*. 2017; 38: 107-110. DOI: 10.1016/j.ijscr.2017.07.020.
- Macciò A, Kotsonis P, Lavra F, Chiappe G, Sanna D, Zamboni F, Madeddu C. Laparoscopic removal of a very large uterus weighting 5320 g is feasible and safe. *BMC Surg*. 2017;17(1):50. DOI: 10.1186/s12893-017-0248-4. Impact factor 1.912
- Macciò A, Lavra F, Chiappe G, Kotsonis P, Sollai G, Zamboni F, Madeddu C. Combined laparoscopic excisional surgery for synchronous endometrial and rectal adenocarcinoma in an obese woman. *J Obstet Gynaecol*. 2016;36(8):1012-1015. DOI: 10.1080/01443615.2016.1234444 Impact factor 0.807

- Macciò A, Kotsonis P, Chiappe G, Melis L, Zamboni F, Madeddu C. Long-term survival in a patient with abdominal sarcomatosis from uterine leiomyosarcoma: role of repeated laparoscopic surgery in the treatment and follow-up. *J Minim Invasive Gynecol.* 2016;23(6):1003-8. DOI: 10.1016/j.jmig.2016.05.005. Impact factor 3.107
- Macciò A, Chiappe G, Kotsonis P, Nieddu R, Lavra F, Serra M, Onnis P, Sollai G, Zamboni F, Madeddu C. Surgical outcome and complications of total laparoscopic hysterectomy for very large myomatous uteri in relation to uterine weight: a prospective study in a continuous series of 461 procedures. *Arch Gynecol Obstet.* 2016;294(3):525-31. DOI: 10.1007/s00404-016-4075-0 Impact factor 2.283
- Madeddu C, Mantovani G, Gramignano G, Macciò A. Advances in pharmacologic strategies for cancer cachexia. *Expert Opin Pharmacother.* 2015; 16: 2163-2177. DOI:10.1517/14656566.2015.1079621 Impact factor 2.878; number of citations 19
- Madeddu C, Mantovani G, Gramignano G, Astarà G, Macciò A. Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches. *Future Oncol.* 2015;19:2697-2710. DOI: 10.2217/fon.15.195 Impact factor 2.660
- Macciò A, Gramignano G, Madeddu C. A Multi-Targeted Treatment Approach for Anemia and Cachexia in Metastatic Castration-Resistant Prostate Cancer. *J Pain Symptom Manage.* 2015 50(2): e1-e4. DOI: 10.1016/j.jpainsymman.2015.04.014 Impact factor 3.077
- Macciò A, Gramignano G, Madeddu C. Surprising results of a supportive integrated therapy in myelofibrosis. *Nutrition.* 2015;31:239-43. DOI: 10.1016/j.nut.2014.07.016. Impact factor 3.639;
- Macciò A, Madeddu C, Gramignano G, Mulas C, Tanca L, Cherchi MC, Floris C, Omoto I, Barracca A, Ganz T. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. *Haematologica.* 2015;100(1):124-32. DOI: 10.3324/haematol.2014.112813 Impact factor 7.116
- Madeddu C, Gramignano G, Floris C, Murenu G, Sollai G, Macciò A. Role of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer. *J Cell Mol Med.* 2014;18(12):2519-29. DOI: 10.1111/jcmm.12413 Impact factor 4.468
- Madeddu C, Gramignano G, Kotsonis P, Paribello F, Macciò A. Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases. *Oncol Lett.* 2014;8(3):1279-1282. DOI: 10.3892/ol.2014.2319 Impact factor 2.311
- Macciò A, Madeddu C, Kotsonis P, Pietrangeli M, Paoletti AM. Large twisted ovarian fibroma associated with Meigs' syndrome, abdominal pain and severe anemia treated by laparoscopic surgery. *BMC Surgery.* 2014;14:38. DOI: 10.1186/1471-2482-14-38 Impact factor 1.912
- Macciò A, Madeddu C, Kotsonis P, Pietrangeli M, Paoletti AM. Successful laparoscopic management of a giant ovarian cyst. *J Obstet Gynaecol.* 2014;34(7):651-2. DOI: 10.3109/01443615.2014.902432 Impact factor 0.807
- Macciò A, Madeddu C.: The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications. a review. *J Mol Med (Berl).* 2013; 91(12):1355-68. DOI: 10.1007/s00109-013-1080-7 Impact factor 4.427

- Mantovani G, Madeddu C, Macciò A. Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. *Drug Design, Development and Therapy*. 2013;7:645-56.
- Macciò A, Madeddu C. Cisplatin: an old drug with a newfound efficacy - From mechanisms of action to cytotoxicity. *Expert Opin Pharmacother*. 2013;14(13):1839-57. DOI: 10.1517/14656566.2013.813934 Impact factor 2.878
- Macciò A, Madeddu C. Management of Anemia of Inflammation in the Elderly. *Anemia Volume 2012 (2012)*, Article ID 563251, DOI:10.1155/2012/563251.
- Mantovani G, Madeddu C, Macciò A. Cachexia and Oxidative stress in cancer: an innovative therapeutic management. *Curr Pharm Des*. 2012;18:4813-8. DOI: 10.2174/138161212803216889

#### Impact Factor 2.208

- Macciò A, Madeddu C, Gramignano G, Mulas C, Floris C, Sanna E, Cau MC, Panzone F, Mantovani G. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. *Gynecol Oncol*. 2012;124(3):417-25. DOI: 10.1016/j.ygyno.2011.12.435 Impact Factor 4.623
- Madeddu C, Dessì M, Panzone F, Serpe R, Antoni G, Cau MC, Montaldo L, Mela Q, Mura M, Astara G, Tanca FM, Macciò A, Mantovani G. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. *Clin Nutr* 2012;31:176-82. doi: 10.1016/j.clnu.2011.10.005. Impact Factor 6.360
- Macciò A, Madeddu C, Mantovani G. Current pharmacotherapy options for cancer anorexia and cachexia. *Expert Opin Pharmacother*. 2012;13(17):2453-7. DOI: 10.1517/14656566.2012.734297

#### Impact factor 2.878

- Macciò A, Madeddu C. Inflammation and ovarian cancer. *Cytokine*. 2012;58(2):133-47. DOI: 10.1016/j.cyto.2012.01.015 Impact factor 2.952
- Macciò A, Madeddu C, Kotsonis P, Caffiero A, Desogus A, Pietrangeli M, Paoletti AM.
- Three cases of laparoscopic myomectomy performed during pregnancy for pedunculated uterine myomas. *Arch Gynecol Obstet*. 2012;286(5):1209-14. DOI: 10.1007/s00404-012-2441-0 Impact factor 2.283
- Macciò A, Madeddu C, Caffiero A, Paoletti AM. Successful pregnancy following myomectomy of a giant uterine myoma: role of a combined surgical approach. *Arch Gynecol Obstet*. 2012;285(6):1577-80. DOI: 10.1007/s00404-011-2197-y Impact factor 2.283
- Macciò A, Madeddu C. Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. *ScientificWorldJournal*. 2011;11:2020-36. DOI: 10.1100/2011/806787 Impact factor 1.524
- Macciò A. Role of inflammation in the evolution of Cancer disease (Editorial) *Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry*. 2011; 10 (4): 246-247.
- Macciò A. Advanced neoplastic disease as immunologic, endocrine and metabolic disorder. *Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry*. 2011; 10 (4): 248-261.

- Macciò A, Madeddu C, Chessa P, Panzone F, Lissoni P, Mantovani G. Oxytocin both increases proliferative response of peripheral blood lymphomonocytes to phytohemagglutinin and reverses immunosuppressive estrogen activity. *In Vivo*. 2010;24(2):157-63. PMID: 20363988. Impact factor 1.541
- Macciò A, Madeddu C, Gramignano G, Mulas C, Floris C, Massa D, Astara G, Chessa P, Mantovani G. Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. *J Mol Med (Berl)*. 2010;88(7):677-86. DOI: 10.1007/s00109-010-0611-8 Impact factor 4.427
- Macciò A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. *Oncologist*. 2010;15(8):894-902. DOI: 10.1634/theoncologist.2010-0020 Impact factor 5.025
- Macciò A, Madeddu C, Chessa P, Mantovani G, Galanello R. Use of erythropoiesis stimulating agents for the treatment of anaemia and related fatigue in a pregnant woman with HbH disease. *Br J Haematol*. 2009; 146 (3): 335-337. DOI: 10.1111/j.1365-2141.2009.07755.x Impact factor 5.518
- Macciò A, Madeddu C, Mantovani G. Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives. *Obesity Review* 2009; 10:660-70. DOI: 10.1111/j.1467-789X.2009.00592.x Impact factor 7.731
- Macciò A, Madeddu C, Panzone F, Mantovani G. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. *Expert Opin Pharmacother*. 2009;10(4):693-703. DOI: 10.1517/14656560902758343 Impact factor 2.878
- Macciò` A, MD, Madeddu C, MD, Sanna E, MD, Panzone F, MD, Volpe A, MD, and Mantovani G, MD Evidence That Human Serum With High Levels of Estrogens Interferes With Immune System Both by Decreasing CD25 Expression on T-Cell and by Increasing Interleukin-2 Availability. *Reprod Sci* 2008 Nov;15(9):961-9. DOI: 10.1177/1933719108322428 Impact factor 2.616
- Macciò A, Madeddu C, Massa D, Astara G, Farci D, Melis GB, Mantovani G. Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients. *J Cell Mol Med* 2009; 13(9b): 3951-9. DOI: 10.1111/j.1582-4934.2008.00408.x Impact factor 4.486
- Maccio A, Madeddu C, Massa D, Mudu MC, Lusso MR, Gramignano G, Serpe R, Melis GB, Mantovani G. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: Role of inflammation in cancer-related anemia. *Blood* 2005; 106:362-367. DOI: 10.1182/blood-2005-01-0160 Impact factor 17.543
- Macciò A., Lai P. Santona M.C., Pagliara L., Melis G.B., Mantovani G.: High Serum Levels of Soluble IL-2 Receptor, Cytokines and C Reactive Protein Correlate with Impairment of T Cell Responses in Patients with Advanced Epithelial Ovarian Cancer. *Gynecol Oncol* 1998; 69:248-252. doi: 10.1006/gyno.1998.4974. PMID: 9648596.
- Macciò A, Mantovani G, Turnu E, Contu G, Artini P, Serri FG, Volpe A: Evidence that granulosa cells inhibit interleukin 1 alpha and interleukin 2 production from follicular lymphomonocytes. *J Assist Reprod Genet* 1993; 10 (8): 493-536. doi: 10.1007/BF01204362. PMID: 8081089.

- Macciò A, Mantovani G, Turnu E, Artini P, Contu G, Volpe A: Preovulatory human follicular fluid inhibits IL1, IL2 production and expression of p55 chain IL2 receptor from in vitro Phytohemagglutinin-stimulated peripheral blood mononuclear cells. *Fertil Steril.* 1994; 2:327-332. doi: 10.1016/s0015-0282(16)56886-1. PMID: 8034080.
- Macciò A, Mantovani G, Serri FG, Mauri A, Andria G, Arangino V, Argiolas A, Del Giacco GS: In vitro estrogen-induced inhibition of PHA-stimulated proliferation of peripheral blood lymphocytes: reversal by recombinant Interleukin 2 and Oxytocin. *J Immunol Res* 1990;2:90-94.
- Mantovani G, Madeddu C, Macciò A. Cachexia and Oxidative stress in cancer: an innovative therapeutic management. *Curr Pharm Des.* 2012; 18(31):4813-8. doi: 10.2174/138161212803216889. PMID: 22632861.
- Mantovani G, Macciò A, Madeddu C, Serpe R, Antoni G, Massa E, Dessì M, Panzone F. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. *J Mol Med.* 2009;88:85-92. doi: 10.1007/s00109-009-0547-z. Impact Factor 5.004
- Madeddu C, Macciò A, Mantovani G. Metabolic changes in cancer patients. *Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry.* 2011; 10 (4): 281-285.
- Mantovani G, Macciò A, Madeddu C, Serpe R, Gramignano G, Panzone F. Antioxidant agents alpha lipoic acid, N-Acetyl cysteine and MESNA (2-mercaptoethane sulfonate) are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients. *Current Trends in Immunology* 2011; 11: 65-74.
- Madeddu C, Macciò A, Astara G, Massa E, Dessì M, Antoni G, Panzone F, Serpe R, Mantovani G. Open phase II study on efficacy and safety of an oral amino acid functional cluster supplementation in cancer cachexia. *Mediterranean Journal of Nutrition and Metabolism.* 2010;3 (2): 165-172.
- Mantovani G, Macciò A, Madeddu C, Serpe R, Massa E, Dessì M, Panzone F, Contu P. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. *Oncologist.* 2010;15(2):200-11. DOI: 10.1634/theoncologist.2009-0153 Impact Factor 5.025
- Madeddu C, Macciò A, Panzone F, Tanca FM, Mantovani G. Medroxyprogesterone acetate in the management of cancer cachexia. *Expert Opin Pharmacother.* 2009;10(8):1359-66. DOI: 10.1517/14656560902960162 Impact Factor 2.878
- Mantovani G, Macciò A, Madeddu C, Gramignano G, Serpe R, Massa E, Dessì M, Tanca FM, Sanna E, Deiana L, Panzone F, Contu P, Floris C. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. *Nutrition.* 2008;24(4):305-13. DOI: 10.1016/j.nut.2007.12.010 Impact Factor 3.639
- Mantovani G, Maccio A, Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G, Deiana L.: A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. *Cancer Epidemiol Biomarkers Prev.* 2006;15(5):1030-4. DOI: 10.1158/1055-9965.EPI-05-0538 Impact Factor 4.344
- Mantovani G, Maccio A, Madeddu C, Serpe R, Massa E, Gramignano G, Lusso MR, Correli N and Rinaldi A. Selenium is effective in inducing lymphocyte progression through cell cycle in cancer

patients: potential mechanisms for its activity. *J Experimental Therapeutics and Oncology* 2004;4:69-78. PubMed ID:15255293

- Mantovani G, Maccio A, Madeddu C, Massa E. Cancer-related cachexia and oxidative stress: beyond current therapeutic options. *Expert Rev Anticancer Ther.* 2003;3(3):381-92. DOI:10.1586/14737140.3.3.381. Impact factor 3.573
- Mantovani G, Maccio A, Madeddu C, Mura L, Gramignano G, Lusso MR, Massa E, Mocci M, Serpe R. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. *J Mol Med.* 2003;81(10):664-73. DOI: 10.1007/s00109-003-0476-1 Impact Factor 4.101
- Mantovani G, Macciò A, Madeddu C, Mura L, Massa E, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L. Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment. *J Environ Pathol Toxicol Oncol* 2003; 22: 17-28. DOI:10.1615/JEnvPathToxOncol.v22.i1.20
- Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L, Mocci M, Massa E. The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. *Free Radic Res* 2003; 37: 213-223. DOI: 10.1080/10715760303849 Impact Factor 2.839
- Mantovani G, Macciò A, Madeddu C, Mura L, Massa E, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L. Reactive oxygen species, antioxidant mechanisms and serum cytokine levels in cancer patients: impact of an antioxidant treatment. *J Cell Mol Med* 2002;6: 570-582. DOI: 10.1111/j.1582-4934.2002.tb00455.x Impact Factor 4.486
- Mantovani G, Macciò A, Madeddu C, Mulas C, Massa E, Astara G, Ferreli L, Mudu MC, Gramignano G, Murgia V, LussoMR, Mocci M, Cardia A and Mura L. Phase II Study of subcutaneously administered Interleukin 2 in combination with Medroxyprogesterone Acetate and Antioxidant Agents as maintenance treatment in advanced cancer patients responders to previous chemotherapy *Oncol Rep* 2002;9: 887-896. PMID: 12066227 Impact Factor 1.256
- Mantovani G, Macciò A, Mulas C, Massa E, Madeddu C, Mura L, Contu P, Versace R. Dose-intense Phase II study of weekly Cisplatin and Epidoxorubicin plus Medroxyprogesterone Acetate and Recombinant Interleukin 2 in Stage IIIB-IV Non-Small-Cell Lung Cancer. *Oncol Rep* 2002;9: 661-670. WOS:000175196800039. PMID: 11956647 Impact Factor 1.256
- Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Mulas C, Mudu MC, Murgia V, Camboni P, Massa E, Contu P, Rinaldi A, Sanjust E, Atzei D and Elsener B. Quantitative evaluation of oxidative stress, chronic inflammatory indexes and leptin in cancer patients: correlation with stage and performance status. *Int J Cancer* 2002; 98:84-91. DOI: 10.1002/ijc.10143 Impact Factor 4.056
- Mantovani G, Macciò A, Madeddu C, Massa E, Mudu MC, Mulas C, Gramignano G, Massidda S, Murgia V, Lusso MR, Mura L. Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy. *Int J Oncol* 2001; 18, 383-391. PMID: 11172608. Impact Factor 2.330

- Mantovani G, Macciò A, Mura L, Massa E, Mudu MC, Mulas C, Lusso MR, Madeddu C, Gramignano G, Piras MB, Massa D. Serum values of proinflammatory cytokines inversely correlate with serum leptin levels in patients with advanced stage cancer at different sites. *J Mol Med* 2001;79:406-414. PMID: 11466563 Impact Factor 3.498
- Mantovani G, Macciò A, Massa E. Managing Cancer-Related Anorexia/Cachexia (CAC). *DRUGS* 2001; 61 (4): 499-514. DOI: 10.2165/00003495-200161040-00004. PMID: 11324680. Impact factor 6.189
- Mantovani G, Macciò A, Mura L, Massa E, Mudu MC, Mulas C, Lusso MR, Madeddu C, Dessì A. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. *J Mol Med* 2000; 78:554-61. DOI: 10.1007/s001090000137. PMID: 11199328. Impact factor 4.427
- Mantovani G, Macciò A, Melis G, Mura L, Massa E, Mudu MC. Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha-lipoic acid and N-acetyl cysteine. *Int J Cancer* 2000; 86:842-847. DOI: 10.1002/(sici)1097-0215(20000615)86:6<842::aid-ijc13>3.0.co;2-k. PMID: 10842199. Impact factor 5.145
- Mantovani G, Macciò A, Lai P, Massa E, Massa D, Mulas C, Succu G, Mudu MC, Manca G, Versace R, Pisano A: Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung,cancer. *J Immunother* 2000;23(2):267-74. doi: 10.1097/00002371-200003000-00011. PMID: 10746553. Impact factor 4.110
- Mantovani G, Macciò A, Massa E, Lai P, Manca G, Mudu C, Versace R, Pusceddu G. Relationships between Fas expression, activation molecule CD25 and functional activity of tumor associated lymphomonocytes (TALM) from neoplastic effusions. *Oncol Rep* 1999;6: 235-9. DOI: 10.3892/or.6.1.235. PMID: 9864435. Impact factor 1.256
- Mantovani G, Maccio A, Lai P, Esu S, Massa E, Santona MC, Massa D, Dessi D, Ghiani M: Medroxyprogesterone acetate and megestrol acetate reduce cisplatin-induced serotonin release from human peripheral blood mononuclear cells of cancer patients. *Oncol Rep.* 1998;5(1):121-4. DOI: 10.3892/or.5.1.121. PMID: 9458305. Impact factor 1.256
- Mantovani G, Macciò A, Lai P, Massa E, Ghiani M, Santona MC. Cytokine involvement in cancer anorexia/Cachexia. Role of Megestrol acetate and Medroxyprogesterone acetate on cytokine downregulation and improvement of clinical simptoms. *Critical Reviews in Oncogenesis* 1998; 9: 99-106. DOI: 10.1615/critrevoncog.v9.i2.10. PMID: 9973244.
- Mantovani G, Macciò A, Astara G, Curreli L, Ghiani M, Lai P, Santona MC. Quality of Life in Cancer Patients: Cancer related quality of life. *Cancer Update* 1997;5:1-2.
- Mantovani G, Macciò A, Esu S, Lai P, Santona MC, Tetti R, Melis GB, Del Giacco GS. Medroxyprogesterone acetate reduces the production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. *Biochemical Society Transactions* 1997;25: 296S. DOI: 10.1042/bst025296s. PMID: 9191340. Impact factor 5.160
- Mantovani G, Macciò A, Lai P, Massa E, Ghiani M, Santona MC. Cytokine involvement in cancer anorexia/cachexia. Role of megestrol acetate and medroxyprogesterone acetate on cytokine

downregulation and improvement of clinical symptoms. *Semin Oncol* 1998;25 (Suppl 6): 45-52. PMID: 9625383. Impact factor 4.213

- Mantovani G, Macciò A, Pisano M, Versace R, Lai P, Esu S, Ghiani M, Dessì D, Melis GB, Del Giacco GS. Tumor-associated lymphomonocytes (TALM) from neoplastic effusions are immunologically defective in comparison with patient autologous PBMC but are capable of releasing high levels of various cytokines. *Int J Cancer* 1997; 71:724-731. DOI: 10.1002/(sici)1097-0215(19970529)71:5<724::aid-ijc6>3.0.co;2-t. PMID: 9180137. Impact factor 5.145
- Mantovani G, Macciò A, Lai P, Esu S, Ghiani M, Dessì D, Massa E, Melis GB, Del Giacco G. Tumor-Associated Lymphomonocytes (TALM) from neoplastic effusions secondary to ovarian cancer are immunologically defective but are able to release cytokines. *Oncology Reports* 1997; 4: 247-251. DOI: 10.3892/or.4.5.1051. PMID: 21590194 Impact factor 1.256
- Mantovani G, Macciò A, Esu S, Lai P, Santona MC, Tetti R, Melis GB, Del Giacco GS. Medroxyprogesterone acetate reduces the production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells: a possible mechanism explaining its immunological and clinical effects. *Eur J Cancer* 1997;33(4):602-607.
- Mantovani G, Macciò A, Versace R, Pisano M, Lai P, Esu S, Ghiani M, Dessì D, Cherchi R, Melis GB, Del Giacco GS. Tumor-associated lymphomonocytes from neoplastic effusions of patients with different primary tumours are able to release cytokines. *Journal of BUON* 1996;1: 41-45.
- Mantovani G, Macciò A, Esu S, Lai P. Evidence that cisplatin induces serotonin release from human peripheral blood mononuclear cells and that methylprednisolone inhibit this fact. *Eur J Cancer* 1996; 32A:1983-1985. doi: 10.1016/0959-8049(96)00204-3. PMID: 8943685. Impact factor 7.257
- Mantovani G, Macciò A, Versace R, Pisano M, Lai P, Esu S, Ghiani M, Dessì D, Cherchi R, Melis GB, Del Giacco GS. Cytokine release of tumor-associated lymphocytes (TAL) from patients with neoplastic pleural and peritoneal effusions. *Tumor Targeting* 1996;2:7-16.
- Mantovani G, Macciò A, Curreli L, Bianchi A, Ghiani M, Santona MC. Comparison of granisetron vs ondansetron vs tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. *Cancer* 1996;77:941-948. PMID: 8608488. Impact factor 5.742
- Mantovani G, Macciò A, Versace R, Pisano M, Lai P, Esu S, Ghiani M, Dessì D, Turnu E, Santona MC, Cherchi R, Del Giacco GS. Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC. *J Mol Med* 1995;73:409-416. DOI: 10.1007/BF00240140. PMID: 8528743. Impact factor 4.427
- Mantovani G, Macciò A, Curreli L, Lampis B, Ghiani M, Bianchi A, Contu P. Comparison of oral 5-HT3-Receptor Antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin. *Oncol Rep* 1998; 5:273-280. Impact factor 1.256
- Mantovani G, Macciò A, Lai P, Ghiani M, Turnu E, Del Giacco GS: Membrane-bound/soluble IL-2 receptor (IL-2R) and levels of IL1-alpha, IL-2 and IL-6 in the serum and in the PBMC

culture supernatants from 17 patients with hematological malignancies. *Cell Biophys* 1995;27:1-14. Impact factor 2.073

- Mantovani G, Macciò A, Bianchi A, Curreli L, Ghiani M, Santona MC, Del Giacco GS. Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. *Int J Clin Lab Res* 1995; 25:135-141.
- Mantovani G, Macciò A, Esu S, Lai P, Ghiani M, Turnu E, Contu G, Volpe A, Del Giacco GS: Lack of correlation between defective cell-mediated immunity and levels of secreted or circulating cytokines in a study of 90 cancer patients. *Int J Oncol* 1994;5:1211-1217.
- Mantovani G, Macciò A, Lai P, Turnu E, Del Giacco GS. Study of peripheral blood lymphocyte subsets distribution and IL-2 receptor (IL-2 R) p55-p75 subunits expression in patients with cancer of different sites. *Cell Biophys* 1994;24/25:301-305.
- Scambia G, Benedetti Panici P, Contu G, De Vincenzo R, Ferrandina G, Isola G, Macciò A, Mancuso S. Mechanisms and modulation of resistance to anthacyclines (Review). *Int J Oncol* 1994;4:1-8.
- Mantovani G, Macciò A, Astarà G, Contini L, Esu S, Littera S, Sinico L, Arangino V, Lai P, Proto E, Pusceddu G, Balestrieri A, Del Giacco GS. Membrane-bound and soluble IL-2 receptor, p55 and p75 chains, on peripheral blood mononuclear cells from patients with solid malignancies. *Cell Biophys* 1993;22:79-99.
- Mantovani G, Macciò A, Zucca MV, Serra MC, Proto E, Locci F, Arangino V, Manduco D, Sulis G, Puxeddu P, Del Giacco GS: Immunologic assessment determined by response to IL-2 and immunophenotyping of tumor-infiltrating lymphocytes, of invaded and non invaded lymph nodes and of peripheral blood lymphocytes from twenty-one patients with primary laryngeal cancer. *J Biol Regul Homeost Agents* 1989;3:25-34.
- Mantovani G, Madeddu C, Macciò A, Massa E, Gramignano G, Serpe R. Antioxidant therapy for the treatment of oxidative stress associated to cancer and cancer-related anorexia/cachexia. *Current Nutrition and food science* 2007; 3(3): 184-93.
- Tanca FM, Madeddu C, Macciò A, Serpe R, Panzone F, Antoni G, Massa E, Astarà G, Mantovani G. New perspective on the nutritional approach to cancer-related anorexia/cachexia. Preliminary results of a randomized phase III clinical trial with five different arms of treatment. *Mediterranean journal of nutrition and metabolism* 2009; 2(1): 29-36.
- Mantovani G, Madeddu C, Maccio A, Gramignano G, Lusso MR, Massa E, Astarà G, Serpe R. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. *Cancer Epidemiol Biomarkers Prev* 2004;13:1651-9. PMID: 15466983. Impact factor 4.344
- Mantovani G, Madeddu C, Gramignano G, Serpe R, Massa E, Deiana L, Macciò A. An innovative treatment approach for cancer-related anorexia/cachexia and oxidative stress: background and design of an ongoing, phase III, randomized clinical trial. *Support Cancer Ther.* 2007;4(3):163-7. DOI: 10.3816/SCT.2007.n.011. PMID: 18632483. ISSN1543-2912
- Madeddu C, Dessì M, Panzone F, Serpe R, Antoni G, Cau MC, Montaldo L, Mela Q, Mura M, Astarà G, Tanca FM, Macciò A, Mantovani G. Randomized phase III clinical trial of a combined treatment

with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. *Clin Nutr.* 2012;31(2):176-82. DOI: 10.1016/j.clnu.2011.10.005. Epub 2011 Nov 1. PMID: 22047681. Impact factor 6.360

- Busquets S, Serpe R, Toledo M, Betancourt A, Marmonti E, Orpí M, Pin F, Capdevila E, Madeddu C, López-Soriano FJ, Mantovani G, Macciò A, Argilés JM. l-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer. *Clin Nutr.* 2012;31(6):889-95. DOI: 10.1016/j.clnu.2012.03.005. Impact Factor 6.360
- Gramignano G, Lusso MR, Madeddu C, Massa E, Serpe R, Deiana L, Lamonica G, Dessi M, Spiga C, Astará G, Maccio A, Mantovani G. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. *Nutrition.* 2006;22(2):136-45. DOI: 10.1016/j.nut.2005.06.003 Impact factor 3.369
- Mantovani G, Madeddu C, Gramignano G, Lusso MR, Mocci M, Massa E, Ferreli L, Astará G, Maccio A, Serpe R. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters. *J Exp Ther Oncol.* 2003; 3(4):205-19. DOI: 10.1046/j.1359-4117.2003.01096.x. PMID: 14567291.
- Mantovani G, Massa E, Astará G, Murgia V, Gramignano G, Ferreli L, Camboni P, Lusso MR, Mocci M, Madeddu C, Mura L, Mudu MC, Proto E, Tore G, Mura M, Macciò A, Ferreli A, Amichetti M. Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: A phase II study with organ-sparing purposes. *Oncol Rep* 2003; 10: 759-766. PMID: 12684655. Impact factor 1.256
- Mantovani G, Massa E, Astará G, Murgia V, Gramignano G, Lusso MR, Camboni P, Ferreli L, Mocci M, Perboni S, Mura L, Madeddu C, Macciò A. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. *Oncol Rep* 2003; 10: 197-206. PMID: 12469169. Impact factor 1.256
- Mantovani G, Proto E, Massa E, Mulas C, Madeddu C, Mura L, Mudu MC, Astará G, Murgia V, Gramignano G, Ferreli L, Camboni P, Lusso MR, Mocci M, Tore G, Mura M, Macciò A, Amichetti M. Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study with organ-sparing purposes evaluating feasibility, effectiveness and toxicity. *Int J Oncol* 2002; 20: 419-427. PMID: 11788911. Impact factor 2.931
- Mantovani G, Proto E, Macciò A, Massa E, Mulas C, Mudu MC, Massidda S, Massa D, Murgia V, Ferreli L, Succu G, Astará G, Tore G, Mura M and Maxia G. Phase II Study of Induction Chemotherapy followed by Concomitant Chemoradiotherapy in advanced Head and Neck Cancer: clinical outcome, toxicity and organ/function preservation. *Int J Oncol* 2000; 16: 1227-1233. DOI: 10.3892/ijo.16.6.1227. PMID: 10812000. Impact factor 2.931
- Mantovani G, Curreli L, Macciò A, Ghiani M, Dessì D, Massa D, Mulas C, Succu G, Contu P. Prevention of Nausea and vomiting (N&V) in cancer patients receiving HD cisplatin. Assessment of the potential antiemetic activity of Transdermal Fentanyl (TTS-F) compared to standard antiemetic

treatment in acute and delayed N&V: first clinical report. *Anticancer Res.* 1999; 19(4C):3495-502. PMID: 10629642. Impact factor 1.994

- Mantovani G, Ghiani M, Curreli L, Macciò A, Massa D, Succu G, Lai P, Massa E, Mudu C, Astara G. Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients. *Oncol Rep* 1999;6 421-6. DOI: 10.3892/or.6.2.421. PMID: 10023014. Impact factor 1.256
- Mantovani G, Ghiani M, Lai P, Macciò A, Dessì D, Succu G, Massa D, Curreli L, Mulas C, Esu S, Proto E, Cadeddu G, Tore G. Clinical evaluation of two dosages and schedules of Ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a Phase II randomized study. *Oncol Rep* 1998;5:1499-1505. DOI: 10.3892/or.5.6.1499. PMID: 9769395. Impact factor 1.256
- Mantovani G, Bianchi A, Curreli L, Ghiani M, Astara G, Lampis B, Santona MC, Dessì D, Esu S, Lai P, Massa E, Macciò A, Proto E: Clinical and immunological evaluation of schizophyllan (SPG) in combination with standard chemotherapy in patients with head and neck squamous cell carcinoma. *Int J Oncol* 1997; 10: 213-221. DOI: 10.3892/ijo.10.1.213. PMID: 21533366. Impact factor 2.931
- Mantovani G, Esu S, Astara G, Lampis B, Macciò A, Usai P, Santa Cruz G, Mura E, Ferreli A: Primary CD30 positive anaplastic Large-Cell Lymphoma associated with adult-onset Celiac Disease and presenting with skin lesions. *Acta Haematologica* 1995; 94:48-51. DOI: 10.1159/000203971. PMID: 7544524. Impact factor 1.196
- Mantovani G, Serri FG, Macciò A, Castelli P, Benedetti P, Scambia G, Santus S, Paderi R, Murtas MG, Ferreli A, Mancuso S, Del Giacco GS: Functional and surface phenotype study of lymphocyte subsets in peripheral blood and lymph nodes of breast cancer patients *Cancer Detect Prev* 1989; 13:323-332. PMID: 2743354.
- Mantovani G, Coiana A, Massidda A, Proto E, Floris C, Pusceddu G, Macciò A, Del Giacco GS: Role of Interleukin 2 (IL-2) in the cancer-related immunodeficiency: in vitro response to IL-2, production of IL-2 and IL-2 receptor expression in patients with advanced cancer. *Cancer Detect Prev* 1988; 12:149-159. PMID: 3263194.
- Scambia G, Benedetti Panici PL, Macciò A, Castelli P, Serri F, Mantovani G, Massidda B, Iacobelli S, Del Giacco GS, Mancuso S Effects of antiestrogen and progestin on immune functions in breast cancer patients. *Cancer* 1988; 61:2214-2218. DOI: 10.1002/1097-0142(19880601)61:11<2214::aid-cncr2820611115>3.0.co;2-v. PMID: 2966668. Impact factor 5.742
- Mantovani G, Coiana A, Massidda A, Proto E, Floris C, Macciò A, Pusceddu G, Del Giacco GS: Interleukin 2 (IL-2) relationships with the cancer-related immunodeficiency: in vitro response to exogenous IL-2 by PHA-activated and non PHA-activated peripheral blood mononuclear cells from cancer patients. *Diagn Clin Immunol* 1987; 5:104-111. PMID: 3497733.
- Mantovani G, Coiana A, Massidda A, Locci F, Loy M, Piludu G, Piras MC, Macciò A, Del Giacco GS: Peripheral blood lymphocyte response to recombinant and non recombinant Interleukin 2 in previously treated patients with Hodgkin's disease, long-time off-therapy. *Eur J Haematol* 1987; 38:179-186. doi: 10.1111/j.1600-0609.1987.tb01159.x. PMID: 3496236.

- Impact factor 2.22
- Mantovani G, Coiana A, Massidda A, Proto E, Floris C, Macciò A, Pusceddu G, Del Giacco GS: Interleukin 2 (IL2) and cancer In vitro response to exogenous R and non-R IL2 by PHA-activated and non-PHA-activated PBMC from patients with cancer. *Journal of Experimental Pathology* 1987; 3:539-547.
- Mantovani G, Coiana A, Cossu F, Floris C, Proto E, Macciò A, Pisano G, Taglieri G, Puxeddu G, Del Giacco GS: Peripheral blood lymphocyte response to exogenous Interleukin 2 by PHA-prestimulated and non PHA-prestimulated cells in patients with cancer. *Tumori* 1986; 72:375-382

#### CHAPTERS IN INTERNATIONAL BOOKS

- Maccio A, Madeddu C. Inflammation and Ovarian Cancer. In: *Ovarian cancer. Basic Science perspective*. Edited y Samir A. Farghaly, InTech, Rijeka, Croatia, pp17-50. ISBN 978-953-307-812-0
- Macciò A, Madeddu C. Body mass index and estrogen-dependent breast cancer in postmenopausal women: Pathogenetic mechanisms and new therapeutic perspectives. In: *New Trends in Body Mass Index Research, 2012*, pp. 1-36. Vermeulen A, De Smet E (Eds), Nova Science Pulisher, Inc. New York (USA).
- ISBN 978-161942430-2
- Mantovani G, Madeddu C, Macciò A. Antioxidants, anorexia/cachexia, and oxidative stress in patients with advanced-stage cancer. In: *Oxidative Stress in Cancer Biology and Therapy, 2012*, pp. 373-385. Douglas R. Spitz, Kenneth J. Dornfeld, Koyamangalath Krishnan, David Gius (Eds), Humana Press, Inc, Humana Press, Totowa, NJ. ISBN: 978-161779397-4;978-161779396-7.
- Madeddu C, Macciò A, Mantovani G. Vitamin C supplementation in cancer cachexia and related-oxidative stress. In *Vitamin C: Nutrition, Side Effects and Supplements, 2011*, pp. 289-298, Jackson CM (Ed). Nova Science Publishers, Inc., Hauppauge, N.Y. (USA). ISBN: 978-161728754-1
- Mantovani G, Macciò A, Madeddu C, Gramignano G. L-carnitine supplementation on quality of life and other health measures. In: *“Handbook of Disease Burden and Quality of Life Measures”*, Springer Science+Business Media LLC 2010 (USA), pp 2047-2070.
- Macciò A, Madeddu C and Mantovani G. Glucose metabolism. In: *Cachexia and Wasting: A Modern Approach*. Mantovani G (ed), Springer, Milan, Italy, pp195-203. ISBN 10-88-470-0471-3
- Mantovani G, Madeddu C, Macciò A, Gramignano G, Lusso MR, Massa E, Astarà G, Serpe R. A phase II study with antioxidants, bothin the diet an supplemented, pharmaco-nutritional support, progesterone and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia-cachexia and oxidative stress. In: *Cachexia and Wasting: A Modern Approach*. Mantovani G (ed), Springer, Milan, Italy, pp 685-698. ISBN 10-88-470-0471-3

#### Publications in National Books

- Macciò A, Madeddu C, Mantovani G. Cancer Anemia. Clinical Implications, Etiopathogenetic Considerations, and Therapeutic Possibilities. Il Pensiero Scientifico Editore, Rome, Italy.
- Madeddu C, Macciò A, Mantovani G. Energy Metabolism and the Metabolism of Various Nutrients in Cachexia. In: *Neoplastic Cachexia and Nutritional Disorders in Cancer Patients*, edited by Giovanni Mantovani, pp. 41-48.

- Mantovani G, Madeddu C, Macciò A. An Innovative Dietary, Pharmaconutritional, and Pharmacological Treatment of Cancer-Related Cachexia/Oxidative Stress. In: Neoplastic Cachexia and Nutritional Disorders in Cancer Patients, edited by Giovanni Mantovani, pp. 115-134.

Authorization Statement:

*I hereby authorize the processing of my personal data pursuant to Legislative Decree 30 June 2003 n.196 "Code regarding the protection of personal data" and Article No. 13 of GDPR 679/16.*